

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2004/036492

International filing date: 03 November 2004 (03.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/516,734  
Filing date: 04 November 2003 (04.11.2003)

Date of receipt at the International Bureau: 17 May 2008 (17.05.2008)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 17, 2008

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.


APPLICATION NUMBER: 60/516,734

FILING DATE: November 04, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/36492

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US60/516,734

Certified by



Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

**INVENTOR(S)**

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Sharon M.	Wahl	North Potomac, MD
Nancy	Vazquez-Maldonado	Chevy Chase, MD
Teresa	Greenwell-Wild	Gaithersburg, MD

☐ Additional inventors are being named on the \_\_\_\_\_ separately numbered sheets attached hereto
**TITLE OF THE INVENTION (500 characters max)**

Methods and Compositions for the Inhibition of HIV-1 Replication

Direct all correspondence to:

**CORRESPONDENCE ADDRESS**

Customer Number

28410

OR

Type Customer Number here

Firm or  
Individual Name

28410

PATENT, TRADEMARK OFFICE

Address

Address

City

State

ZIP

Country

Telephone

Fax

**ENCLOSED APPLICATION PARTS (check all that apply)**

Specification Number of Pages

76



CD(s), Number



Drawing(s) Number of Sheets

11



Other (specify)



Application Data Sheet. See 37 CFR 1.76

**METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT**

Applicant claims small entity status. See 37 CFR 1.27.



A check or money order is enclosed to cover the filing fees



The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:

50-0548



Payment by credit card. Form PTO-2038 is attached.

FILING FEE  
AMOUNT (\$)

\$160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.



No.



Yes, the name of the U.S. Government agency and the Government contract number are: NIDCR, NIH,

Dept. Health and Human services

Respectfully submitted,

SIGNATURE

Date

11/04/2003

TYPED or PRINTED NAME

Jeffrey I. Auerbach

TELEPHONE

(301) 896-0600

REGISTRATION NO.

32,680

(if appropriate)

Docket Number:

03514.160B

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

## **Title of the Invention**

# **Methods and Compositions for the Inhibition of HIV-1 Replication**

## **Field of the Invention**

5           This invention relates to methods and compositions for the attenuation of  
HIV-1 replication in human cells, and especially in human macrophages. The  
invention particularly concerns the use of inhibitors of P21 (CDKN1A) expression  
to attenuate such replication. The invention particularly concerns the use of  
antisense P21 oligonucleotides and/or 2-cyano-3,12-dioxooleana-1,9-dien-28-oic  
10 (CDDO) to attenuate such replication.

## **Statement of Governmental Interest**

          This invention was funded by the National Institutes of Health, Department  
of Health and Human Services. The United States Government has certain rights  
to this invention.

## **15 Background of the Invention**

          Human immunodeficiency virus-1 (HIV-1) is the causative agent of  
acquired immune deficiency syndrome (AIDS) and related disorders (Gallo, R.C.  
*et al.* (1983) "Isolation of human T-cell leukemia virus in acquired immune  
deficiency syndrome (AIDS)," *Science* 220(4599):865-7; Barre-Sinoussi, F. *et al.*  
20 "ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR  
ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)," (1983) *Science* 220:868-  
870; Gallo, R. *et al.* (1984) "FREQUENT DETECTION AND ISOLATION OF  
CYTOPATHIC RETROVIRUSES (HTLV-III) FROM PATIENTS WITH AIDS AND AT  
RISK FOR AIDS," *Science* 224:500-503; Teich, N. *et al.* (1984) "RNA TUMOR  
25 VIRUSES," Weiss, R. *et al.* (eds.) Cold Spring Harbor Press (NY) pp. 949-956).

T lymphocytes and macrophages expressing CD4 and the seven transmembrane chemokine co-receptors CXCR4 and CCR5 are susceptible to HIV-1 infection (Berger, E.A. *et al.* (1999) "CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS; ROLES IN VIRAL ENTRY, TROPISM, AND DISEASE," *Annu. Rev. Immunol.* 17:657-700). In contrast to CD4<sup>+</sup> lymphocytes, HIV-1 infected macrophages can resist cell death despite viral infection. Viruses that are shed from infected macrophages may serve as a reservoir for the infection of additional cells (Wahl, S.M. *et al.* (1996) In: *MACROPHAGE FUNCTION IN HIV INFECTION*, pages 303-336; Orenstein, J.W. (2001) "THE MACROPHAGE IN HIV INFECTION," *J Immunobiology* 204(5):598-602; Balestra, E. *et al.* (2001) "MACROPHAGES: A CRUCIAL RESERVOIR FOR HUMAN IMMUNODEFICIENCY VIRUS IN THE BODY," *J Biol. Regul. Homeost. Agents* 15:272-276; Igarashi, T. *et al.* (2001) "MACROPHAGE ARE THE PRINCIPAL RESERVOIR AND SUSTAIN HIGH VIRUS LOADS IN RHESUS MACAQUES AFTER THE DEPLETION OF CD4<sup>+</sup> T CELLS BY A HIGHLY PATHOGENIC SIMIAN IMMUNODEFICIENCY VIRUS/HIV TYPE 1 CHIMERA (SHIV): IMPLICATIONS FOR HIV-1 INFECTIONS OF HUMANS," *Proc. Natl. Acad. Sci. U.S.A.* 98:658-663; Garbuglia, A.R. *et al.*, (2001) "DYNAMICS OF VIRAL LOAD IN PLASMA AND HIV DNA IN LYMPHOCYTES DURING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): HIGH VIRAL BURDEN IN MACROPHAGES AFTER 1 YEAR OF TREATMENT," *J Chemother* 13:188-194).

The persistence of HIV during highly active antiviral therapy, and poor susceptibility of macrophages to antiviral therapy (Igarashi, T. *et al.* (2001) "MACROPHAGE ARE THE PRINCIPAL RESERVOIR AND SUSTAIN HIGH VIRUS LOADS IN RHESUS MACAQUES AFTER THE DEPLETION OF CD4<sup>+</sup> T CELLS BY A HIGHLY PATHOGENIC SIMIAN IMMUNODEFICIENCY VIRUS/HIV TYPE 1 CHIMERA (SHIV): IMPLICATIONS FOR HIV-1 INFECTIONS OF HUMANS," *Proc Natl Acad Sci U S A* 98:658-63; Garbuglia, A.R. *et al.* (2001) "DYNAMICS OF VIRAL LOAD IN PLASMA AND HIV DNA IN LYMPHOCYTES DURING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): HIGH VIRAL BURDEN IN MACROPHAGES AFTER 1 YEAR OF TREATMENT," *J Chemother* 13, 188-94) has intensified the interest in

characterizing the mechanisms underlying infection and replication in this cell population.

Attempts to treat HIV infection have focused on the development of drugs that disrupt the viral infection and replication cycle (see, Mitsuya, H. *et al.* (1991) 5 “TARGETED THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS-RELATED DISEASE,” FASEB J. 5:2369-2381). Such intervention could potentially inhibit the binding of HIV to cell membranes, the reverse transcription of the HIV RNA genome into DNA, the exit of the virus from the host cell and infection of new cellular targets, or inhibition of viral enzymes (see, U.S. Patent No. 6,475,491). Thus, for example, 10 soluble CD4 has been developed in an effort to competitively block the binding of HIV to lymphocytes (Smith, D.H. *et al.* (1987) “BLOCKING OF HIV-1 INFECTIVITY BY A SOLUBLE, SECRETED FORM OF THE CD4 ANTIGEN,” Science 238:1704-1707; Schooley, R. *et al.* (1990) “RECOMBINANT SOLUBLE CD4 THERAPY IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND AIDS- 15 RELATED COMPLEX. A PHASE I-II ESCALATING DOSAGE TRIAL,” Ann. Int. Med. 112:247-253; Kahn, J.O. *et al.* (1990) “THE SAFETY AND PHARMACOKINETICS OF RECOMBINANT SOLUBLE CD4 (RCD4) IN SUBJECTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND AIDS-RELATED COMPLEX. A PHASE I STUDY,” Ann. Int. Med. 112:254-261; Yarchoan, R. *et al.* (1989) Proc. V<sup>th</sup> Int. 20 Conf. on AIDS, p564, MCP 137). Similarly, the ability of antisense HIV-1 oligonucleotides to inhibit viral replication has been investigated (Maeda N *et al.* (1998) “INHIBITION OF HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 REPLICATION BY ANTISENSE ENV OLIGODEOXYNUCLEOTIDE,” Biochem Biophys Res Commun 243(1):109-112).

25 Unfortunately, although considerable effort has been expended to design effective therapeutics, no curative anti-retroviral drugs against AIDS currently exist. All available therapies are marred by substantial adverse side effects, and by the capacity of HIV to rapidly mutate into forms that are refractive to treatment (Miller, V. *et al.* (2001) “MUTATIONAL PATTERNS IN THE HIV GENOME AND 30 CROSS-RESISTANCE FOLLOWING NUCLEOSIDE AND NUCLEOTIDE ANALOGUE DRUG

EXPOSURE,” *Antivir Ther.* 6 Suppl 3:25-44; Lerma, J.G. *et al.* (2001) “RESISTANCE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TO REVERSE TRANSCRIPTASE AND PROTEASE INHIBITORS: GENOTYPIC AND PHENOTYPIC TESTING,” *J Clin Virol.* 21(3):197-212; O'Brien, W.A. (2000) “RESISTANCE AGAINST REVERSE  
5 TRANSCRIPTASE INHIBITORS,” *Clin Infect Dis.* 30 Suppl 2:S185-92; Wain-Hobson, S. (1996) “RUNNING THE GAMUT OF RETROVIRAL VARIATION,” *Trends Microbiol.* 4(4):135-41; Lange J. (1995) “COMBINATION ANTIRETROVIRAL THERAPY. BACK TO THE FUTURE,” *Drugs.* 49 Suppl 1:32-40). Thus, a continuing need exists for safe and effective anti-HIV therapeutics. The present invention is directed to this  
10 and other needs.

### **Summary of the Invention**

By monitoring virus production by multiple parameters including RNA, p24 antigen expression and ultra-structural detection of viral particles it has been possible to characterize the temporal events associated with the initial virus-  
15 macrophage encounter leading to massive viral replication. In parallel, macrophage changes in gene expression subsequent to virus-receptor interaction have been compared to uninfected cells by cDNA expression array. Analysis of 1200 genes at multiple intervals from initial HIV-1 binding through levels of massive replication (10-14 days) reveals a profile of gene modulation, which  
20 favored virus life cycle, and could influence recruitment and infection of additional HIV-1 host cells. One gene found to be consistently expressed following virus binding and re-expressed at the peak of HIV-1 replication is CDKN1A, also known as p21, Cip1 (Cdk interacting protein), or Waf1 (wild type p53- activated fragment), a protein associated with cell cycle regulation, anti-apoptotic response  
25 and cell differentiation (Dotto, G.P. (2000) “P21(WAF1/CIP1): MORE THAN A BREAK TO THE CELL CYCLE?” *Biochim Biophys Acta* 1471: M43-56). Importantly, modulation of p21 *in vitro* results in suppression of viral replication, and implicated this cellular protein as an interventional target.

In contrast to CD4<sup>+</sup> lymphocytes, HIV-1 infected macrophages typically resist cell death, support viral replication, and facilitate HIV-1 transmission. To elucidate how the virus commandeers macrophage intracellular machinery for its benefit, HIV-1 infected human monocyte-derived macrophages have been  
5 analyzed for viral-induced gene transcription by cDNA expression array. HIV-1 infection induces the transcriptional regulation of genes associated with host defense, signal transduction, apoptosis and cell cycle, including cyclin-dependent kinase inhibitor p21. CDKN1A/p21 expression follows a bimodal pattern with maximum levels occurring during HIV-1 replication. Treatment of macrophages  
10 with p21 anti-sense oligonucleotides inhibits HIV-1 replication. Furthermore, the synthetic triterpenoid and peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) ligand, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), which influences p21 expression, drives a dose dependent suppression of viral replication. These data implicate p21 as a pivotal macrophage facilitator of viral replication.  
15 Moreover, regulators of p21, such as CDDO, provide an interventional approach to modulate HIV-1 replication.

This invention thus relates to methods and compositions for the attenuation of immunodeficiency virus replication in cells, and especially in macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKN1A)  
20 expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides and/or 2-cyano-3,12-dioxooleana-1,9-dien-28-oic (CDDO) to attenuate such replication.

In detail, the invention concerns a method of attenuating the transmission or infection of an immunodeficiency virus into a cell comprising providing to the  
25 cell an inhibitor of p21, wherein the inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least 50% in the transmission or infection of the virus relative to an untreated cell. The invention particularly concerns the embodiments of such method wherein the immunodeficiency virus is a human immunodeficiency virus (HIV), and the cell is a human cell; wherein the  
30 immunodeficiency virus is a feline immunodeficiency virus (FIV), and the cell is a



feline cell; or wherein the immunodeficiency virus is a simian immunodeficiency virus (SIV), and the cell is a simian cell. .

The invention further provides a method of treating AIDS in an individual, comprising providing to HIV-1 infected cells of said individual an amount of a p21  
5 inhibitor sufficient to attenuate the propagation of HIV, wherein said inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least 50% in said propagation of HIV relative to untreated cells.

The invention particularly concerns the embodiments of such methods wherein the inhibitor of p21 is a polynucleotide, and especially wherein the  
10 polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.

The invention particularly concerns the embodiments of such methods wherein the p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule, or of a non-human animal or is a variant of a non-human p21 gene or  
15 p21 cDNA molecule.

The invention further concerns a method of treating AIDS in an individual, comprising providing to HIV-1 infected cells of the individual an amount of a p21 inhibitor sufficient to attenuate the propagation of HIV, wherein the inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least  
20 50% in the propagation of HIV relative to untreated cells.

The invention particularly concerns the embodiments of such methods wherein the polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:4** (and in particular wherein the polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:8** or **SEQ ID NO.:10**) or at least 10  
25 contiguous nucleotides of **SEQ ID NO.:6** (and in particular wherein the polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:7** or **SEQ ID NO.:9**).

The invention further concerns the embodiments of the above methods wherein the inhibitor of p21 is a protein or organic molecule other than a polynucleotide, and in particular concerns the embodiment of such method wherein the inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.

The invention further concerns a pharmaceutical composition comprising an inhibitor of p21 and an excipient or carrier, wherein the inhibitor is present in an amount sufficient to attenuate the propagation of HIV, wherein the inhibitor is present in the composition in an amount sufficient to cause an attenuation of at least 50% in the propagation of HIV relative to untreated cells.

The invention particularly concerns the embodiments of such composition wherein the inhibitor of p21 is a polynucleotide, and especially wherein the polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule. The invention particularly concerns the embodiments of such compositions wherein the p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule, or of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.

The invention particularly concerns the embodiments of such compositions wherein the polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:4** (and in particular wherein the polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:8** or **SEQ ID NO.:10**) or at least 10 contiguous nucleotides of **SEQ ID NO.:6** (and in particular wherein the polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:7** or **SEQ ID NO.:9**).

The invention further concerns the embodiments of the above compositions wherein the inhibitor of p21 is a protein or organic molecule other than a polynucleotide, and in particular concerns the embodiment of such method wherein the inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.

### Brief Description of the Figures

**Figure 1A-1D** illustrate the kinetics of HIV-1 infection in macrophages.

- Figure 1A:** Macrophages are exposed to an R5 strain of HIV-1 for 90 min, washed, and total RNA extracted at the indicated time periods and examined by northern blot analysis with a <sup>32</sup>P-labeled cDNA probe for HIV-1 (Wahl, S.M. *et al.* (1991) "MACROPHAGE- AND ASTROCYTE-DERIVED TRANSFORMING GROWTH FACTOR BETA AS A MEDIATOR OF CENTRAL NERVOUS SYSTEM DYSFUNCTION IN ACQUIRED IMMUNE DEFICIENCY SYNDROME," J Exp Med 173:981-991). Bands of 9.1 and 4.3 kb correspond to viral gag/pol and env mRNA respectively.
- Figure 1B:** Supernatants are collected from infected cultures and examined by ELISA for p24. **Figure 1C:** Macrophages are incubated for the indicated intervals after infection, fixed in gluteraldehyde and process for transmission EM. Original magnification 10,000 X. Ultrastructural analysis of infected cells reveals virions
- Figure 1C and Figure 1D:** in macrophages starting at day 7, a with increasing numbers per cell on day 10 as quantified by counting > 200 cells/time point (**Figure 1D**).

- Figures 2A-2C** illustrate HIV-induced alterations in macrophage transcriptome. **Figure 2A:** Distribution of transcription changes in macrophages 3-6 hr after exposure to HIV. Numbers represent % of total upregulated genes (134/1200) associated with the indicated categories in  $\geq 4$  donors. **Figure 2B** Transcription related genes upregulated  $\geq 2$  fold after 3-6 hours in HIV-1 infected macrophages. **Figure 2C:** Signal transduction-related genes upregulated  $\geq 2$  fold above parallel cultures in descending order.

- Figures 3A-3C** demonstrate increased p21 (CDKN1A) gene expression in HIV-1 infected macrophages. **Figure 3A:** Kinetic profile of p21 expression determined by cDNA expression array following HIV infection. **Figure 3B:** RPA analysis of total mRNA from uninfected and HIV-1 infected macrophages at the indicated time points confirms the enhanced gene expression for p21, with minimal

effect on p53. **Figure 3C:** Graphic representation of densitometry analysis of RPA for p21 and p53 genes normalized to GAPDH.

**Figures 4A-4D** illustrate HIV-1 infected macrophages express increased p21 protein. **Figure 4A:** Overlay images from differential interference contrast (DIC) and immunofluorescence (Texas Red) for p21 labeling in uninfected (1, 2, & 3 ) and virus infected cells (4, 5 & 6), (original image 400X). At higher magnification (original 1000X, 3 & 6), infected macrophages express increased nuclear and cytoplasmic p21 protein when compared with control cells. **Figure 4B:** Densitometric fluorescence intensity analysis using confocal microscopy and Metamorph (Universal Imaging) analysis confirms enhanced nuclear and cytoplasmic p21 protein as represented by the signal intensity across equal line segments sampling nuclear or cytoplasmic regions. **Figure 4C:** Western blot analysis shows enhanced p21 protein expression in HIV-1 infected macrophages. HIV-1 infected cells show at least a two fold increase in p21 protein expression as indicated by densitometry analysis relative to uninfected cells (n=3). **Figure 4D:** Effect of p21 antisense oligonucleotides on HIV-1 replication in macrophages done in duplicate. p21 antisense oligonucleotides (oligo 1 and 2) and control oligonucleotide (oligo 3) were added at a concentration of 50 nM after infection and at the time of refeeding the cells. p24 levels were monitored by ELISA at day 12 (representative experiment).

**Figures 5A-5D** illustrate inhibition of HIV-1 replication in macrophages by CDDO and di-CDDO. **Figure 5A:** Macrophages were pre-treated with CDDO, di-CDDO or DMSO as a control for 45 min and then infected with HIV-1<sub>BaL</sub>. Supernatants were collected on day 12 for p24 Ag analysis by ELISA and cells processed by TEM (**Figure 5B; Figure 5C**). Ultrastructural analysis demonstrates dramatically reduced numbers of infected cells and in the few remaining HIV positive celss, very few virions were identified in cultures treated with CDDO. **Figure 5D:** Cell lysates were generated from 12 days cultures and p21 immunoprecipitated and analyzed by western blot.

**Figure 6** shows the results of siRNA for p21 and its effect on HIV infection.

### **Description of the Preferred Embodiments**

The present invention relates to methods and compositions for the  
5 attenuation of HIV-1 replication in human cells, and especially in human  
macrophages. As used herein, such “attenuation” is preferably of a magnitude  
sufficient to mediate a reduction of at least 50%, more preferably 60%, most  
preferably 80%, or greater in the replication, propagation or transmission of HIV.

The present invention derives in part from the recognition that the  
10 replication of human cells has been found to be tightly coordinated by the  
expression and interaction of an array of cell cycle regulatory proteins. CDKN1A,  
also known as p21Cip1 (Cdk interacting protein), or Waf1 (wild type p53-  
activated fragment), is one of these proteins (Dotto, G.P. (2000)  
“P21(WAF1/CIP1): MORE THAN A BREAK TO THE CELL CYCLE?,” Biochim.  
15 Biophys. Acta 1471:M43-M56). The loss of CDKN1A expression has been  
observed in many tumor cells, suggesting a role for the protein in preventing  
malignant progression. HIV-1 and P21 are discussed in U.S. Patents Nos.:  
6,359,124; 5,965,722; 5,889,156; 6,548,657; 6,511,847; 6,489,163; 6,410,010;  
6,379,965; 6,204,248; 6,133,444; 6,069,134; 5,866,698; 5,861,290; 5,834,440;  
20 5,795,870; 5,766,882; 5,747,469; and 5,693,769.

Although macrophages express the requisite CD4 and chemokine co-  
receptors making them susceptible targets, and R5 viral variants are preferentially  
transmitted, it has remained a challenge to identify HIV-1 positive macrophages  
early after viral exposure in mucosal tissues (Schacker, T. *et al.* (2001)  
25 “PRODUCTIVE INFECTION OF T CELLS IN LYMPHOID TISSUES DURING PRIMARY  
AND EARLY HUMAN IMMUNODEFICIENCY VIRUS INFECTION,” J Infect Dis 183:555-  
562) or in the absence of co-pathogens (Orenstein, J.M. *et al.* (1997)  
“MACROPHAGES AS A SOURCE OF HIV DURING OPPORTUNISTIC INFECTIONS,”  
Science 276:1857-1861). When exposed to HIV-1, monocyte-derived

macrophages (MDM) bind and/or internalize the virus, but the consequences of that interaction are ill defined. Whether the macrophages are triggered by this encounter to modify their phenotypic and functional repertoire or whether HIV-1 enters stealthily, and transiently remains unrecognized by the immune system, it is  
5 important to define the early stages when HIV-1 is gaining a foothold on the immune system and identify key signals which not only promote permissiveness for macrophage HIV-1 infection, but also promote replication.

One aspect of the present invention relates to the recognition that HIV-1 infection stimulates the expression of p21 (CDKN1A) protein in human  
10 macrophages (Vazquez, N. *et al.* (October 2002) "HIV-1 Enhancement of CDKN1A (p21) in Human Macrophages Is Associated with Viral Replication," 5<sup>th</sup> Intl. Workshop on HIV, Cells of Macrophage/Dendritic Lineage and Other Reservoirs, Rome, Italy).

The Vpr gene product of HIV-1 has been found to prevent cell proliferation  
15 by activating p21 expression, suggesting that the upregulation of p21 by HIV-1 Vpr may have important consequences in HIV-1 pathogenesis (Chowdhury I.H. *et al.* (2003) "HIV-1 VPR ACTIVATES CELL CYCLE INHIBITOR P21/WAF1/CIP1: A POTENTIAL MECHANISM OF G2/M CELL CYCLE ARREST," *Virology* 305:371-377). A similar relationship has been disclosed between p21 and HIV-1 Nef (Fackler, O.T.  
20 *et al.* (2000) "P21-ACTIVATED KINASE 1 PLAYS A CRITICAL ROLE IN CELLULAR ACTIVATION BY NEF," *Mol Cell Biol.* 20:2619-2627; Hiipakka M *et al.* (2001) "INHIBITION OF CELLULAR FUNCTIONS OF HIV-1 NEF BY ARTIFICIAL SH3 DOMAINS," *Virology* 286:152-159; Nunn MF *et al.* (1996) "HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 NEF ASSOCIATES WITH A MEMBER OF THE  
25 P21-ACTIVATED KINASE FAMILY," *J Virol.* 70:6157-6161; Renkema GH *et al.* (1999) "IDENTIFICATION OF THE NEF-ASSOCIATED KINASE AS P21-ACTIVATED KINASE 2," *Curr Biol.* 9:1407-1410).

Additionally, Clark, E. *et al.* disclosed that the treatments (such as gamma irradiation) that cause a loss of cell cycle control at the G<sub>1</sub>/S checkpoint cause

HIV-1 infected cells to lose p21 function, and undergo apoptosis (Clark E *et al.* (2000) "LOSS OF G(1)/S CHECKPOINT IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CELLS IS ASSOCIATED WITH A LACK OF CYCLIN-DEPENDENT KINASE INHIBITOR P21/WAF1," J Virol. 74:5040-5052). Gomez, T. *et al.* (5 (<http://www.retroconference.org/2002/Posters/13446.pdf>; "CYTOPLASMIC P21<sup>WAF1/CIP1</sup> PROTECTS U937 PROMONOCYTIC CELLS FROM HIV MEDIATED APOPTOSIS") disclose that the administration of p21-antisense oligonucleotides to promonocytic cells suppressed p21 levels in the cells, and accelerated the death of the HIV-infected cells. The results are stated to indicate that p21 confers resistance to HIV-induced apoptosis (10 in promonocytic cells, and to suggest a possible mechanism for the persistence of its infection in cells such as macrophages.

Antisense oligonucleotides of p21 have been used to affect cell-cycle transit in astrocytoma cells.(Jinbo Liu, *et al.* (2000) "ANTI-SENSE OLIGONUCLEOTIDE OF P21(WAF1/CIP1) PREVENTS INTERLEUKIN 4-MEDIATED (15 ELEVATION OF P27(KIP1) IN LOW GRADE ASTROCYTOMA CELLS," Oncogene 19:661-669). The oligonucleotides had the sequences:

**SEQ ID NO:1:** 5'-ucc gcg ccc agc ucc-3' and

**SEQ ID NO:2:** 5'-ucc gcc cgc agc ucc-3'.

The present invention thus particularly concerns the use of one or more p21 (20 inhibitors to prevent or attenuate the infection of additional host cells, and as such to provide a therapy for AIDS and its simian and feline counterparts.

As used herein, the term "p21 inhibitor" is intended to denote any of a variety of molecules that function to suppress or prevent p21 activity. Such inhibitors can be, for example, transcriptional inhibitors, such as promoter blockers (25 RNAi molecules, antisense polynucleotides of the p21 gene or cDNA, or allelic or non-human species variants thereof. Alternatively, such molecules can comprise translational inhibitors of p21, molecules that inhibit or otherwise interfere with p21 function, etc.

As used herein, an allelic variant of a p21 polynucleotide is a polynucleotide having the sequence of a naturally occurring allele of the p21 gene or cDNA thereof, or of a non-naturally occurring polynucleotide that is 80% homologous, and more preferably 90% homologous, and most preferably comprises a sequence that has at least 12, and more preferably, at least 20 contiguous nucleotides that are identical in sequence to a portion of a naturally occurring p21 gene or cDNA. Examples of such sequences include NCBI accession Nos. BC000312 and BC013967. As used herein, a non-human species variant of a p21 polynucleotide is a polynucleotide having the sequence of the p21 gene or cDNA of a non-human animal, for example a mouse or rat. Examples of such sequences include NM 007669 and U24174.

Antisense molecules suitable for use in the present invention can be identified as polynucleotide molecules having a length of 10-250, or more preferably 10-150, and most preferably, 10-100 nucleotides that are complementary to a portion of **SEQ ID NO.:3** (the human p21 gene, see Xiong, Y. *et al.* (1993) "P21 IS A UNIVERSAL INHIBITOR OF CYCLIN KINASES," *Nature* 366:701-704 (1993); el-Deiry, W.S. *et al.* (1993) "WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION," *Cell* 75:817-825 (1993); Harper, J.W. *et al.* (1993) "THE P21 CDK-INTERACTING PROTEIN CIP1 IS A POTENT INHIBITOR OF G1 CYCLIN-DEPENDENT KINASES," *Cell* 75:805-816) or allelic or non-human species variants thereof, especially the murine p21 gene (NM 007669).

**SEQ ID NO.:3:**

```
1   gctgccgaag tcagttcctt gtggagccgg agctgggagc ggattcgccg
25 51   aggcaccgag gcactcagag gaggtgagag agcggcggca gacaacaggg
    101   gaccccgggc cggcggccca gagccgagcc aagcgtgccc gcgtgtgtcc
    151   ctgcgtgtcc gcgaggatgc gtgttcgagg gtgtgtgctg cgttcacagg
    201   tgtttctgag gcaggcgcca tgtcagaacc ggctggggat gtccgtcaga
    251   acccatgcgg cagcaaggcc tgccgcccgc tcttcggccc agtggacagc
    301   gagcagctga gccgcgactg tgatgcgcta atggcgggct gcattccagga
30 351   ggcccgtgag cgatggaact tcgactttgt caccgagaca ccactggagg
    401   gtgacttcgc ctgggagcgt gtgcggggcc ttggcctgcc caagctctac
    451   cttccacagg ggcccggcgg aggccgggat gagttgggag gaggcaggcg
```



501 gcctggcacc tcacctgctc tgctgcaggg gacagcagag gaagaccatg  
551 tggacctgtc actgtcttgt acccttgtgc ctgctcagg ggagcaggct  
601 gaaggggtccc caggtggacc tggagactct cagggtcgaa aacggcggca  
651 gaccagcatg acagatttct accactccaa acgccggctg atcttctcca  
5 701 agaggaagcc ctaatccgcc cacaggaagc ctgcagtcct ggaagcgcgga  
751 gggcctcaaa ggcccgtctc acatcttctg ccttagtctc agtttgtgtg  
801 tcttaattat tatttgtgtt ttaatttaaa cactcctca tgtacatacc  
851 ctggccgccc cctgcccccc agcctctggc attagaatta tttaaacaaa  
901 aactaggcgg ttgaatgaga ggttcctaag agtgctgggc atttttat  
10 951 tatgaaatac tatttaagc ctctcatcc cgtgttctcc ttttctctc  
1001 tcccggaggt tgggtgggcc ggcttcatgc cagctacttc ctctcccca  
1051 ctgtccgct ggggtgtacc ctctggagg gtgtggctcc tccccatgc  
1101 tgtcacaggc ggttatgaaa ttcacccct tctctggaca ctcacacctg  
1151 aattcttttt catttgagaa gtaaacagat ggcactttga aggggcctca  
15 1201 ccgagtgggg gcatcatcaa aaactttgga gtcccctcac ctctctaag  
1251 gttgggcagg gtgacctga agtgagcaca gcctagggt gagctgggga  
1301 cctggtacc tctggctct tgatacccc ctctgtcttg tgaaggcagg  
1351 ggggaagggtg ggtcctggag cagaccaccc cgcctgccct catggcccct  
1401 ctgacctgca ctggggagcc cgtctcagt ttgagccttt tccctctttg  
20 1451 gctcccctgt accttttgag gagccccagc tacccttctt ctccagctgg  
1501 gctctgcaat tccccctgc tgcctgcct ccccctgtc ctttcccttc  
1551 agtacctct cagctccagg tggctctgag gtgcctgtcc caccaccacc  
1601 cccagctcaa tggactggaa ggggaaggga cacacaagaa gaagggcacc  
1651 ctagttctac ctcaggcagc tcaagcagcg accgccccct cctctagctg  
25 1701 tgggggtgag ggtcccatgt ggtggcacag gcccccttga gtggggttat  
1751 ctctgtgtta ggggtatatg atgggggagt agatcttct aggagggaga  
1801 cactggcccc tcaaatcgtc cagcgacct cctcatccac cccatccctc  
1851 cccagttcat tgcaacttga ttagcagcgg aacaaggagt cagacatttt  
1901 aagatggtgg cagtagaggc tatggacagg gcatgccacg tgggctcata  
30 1951 tgggggtggg agtagttgtc tttcctggca ctaacgttga gcccctggag  
2001 gcactgaagt gcttagtgta cttggagtat tggggtctga ccccaaacac  
2051 cttccagctc ctgtaacata ctggcctgga ctgttttctc tgggtccccc  
2101 atgtgtcctg gtccccgttt ctccacctag actgtaaacc tctcaggggc  
2151 agggaccaca ccctgtactg ttctgtgtct ttcacagctc ctcccacaat  
35 2201 gctgaatata cagcaggtgc tcaataaatg attcttagtg actttaaaaa  
2251 aaaaaaaaa aaaaa

Preferred p21 inhibitors of the present invention thus include polynucleotide fragments of **SEQ ID NO: 4** (the antisense complement of **SEQ ID NO.:3**), or allelic or non-human species variants thereof:

**SEQ ID NO.:4:**

```
5      1  tttttttttt tttttttttt aaagtcacta agaatcattt attgagcacc
      51  tgctgtatat tcagcattgt gggaggagct gtgaaagaca cagaacagta
     101  cagggtgtgg tccctgccct cgagagggtt acagtctagg tggagaaacg
     151  ggaaccagga cacatgggga gccgagagaa aacagtccag gccagtatgt
     201  tacaggagct ggaaggtgtt tggggtcaga cccaataact ccaagtacac
10     251  taagcacttc agtgcctcca ggggctcaac gttagtgcc a gaaagacaa
     301  ctactcccag ccccatatga gccacagtgg catgccctgt ccatagcctc
     351  tactgccacc atcttaaaat gtctgactcc ttgttccgt gctaatacaa
     401  gtgcaatgaa ctggggaggg atgggggtgga tgaggaaggt cgctggacga
     451  tttagggggc cagtgtctcc ctctagaaa gatctactcc cccatcatat
15     501  acccctaaca cagagataac cccactcaag ggggcctgtg ccaccacatg
     551  ggaccctcac ccccacagct agaggagggg gcggtcgctg cttgagctgc
     601  ctgaggtaga actagggtgc cttcttctt gtgtgtccct tccccctcca
     651  gtccattgag ctgggggtgg ggggtggaca ggcacctcag agccacctgg
     701  agctgagagg gtactgaagg gaaaggacaa gggggaggga cagcagcaga
20     751  ggggaattgc agagcccagc tggagaagaa gggtagctgg ggctcctcaa
     801  aaggtacagg ggagccaaag agggaaaagg ctcaacactg agacgggctc
     851  cccagtgcag gtcagagggg ccatgagggc aggcgggggt gtctgtcca
     901  ggacccacc ttccccctgc cttcacaaga cagagggggg tatcaagagc
     951  caggagggt a ccaggtcccc agctcagccc taggctgtgc tcaacttcagg
25    1001  gtcaccctgc ccaaccttag aggaggtgag gggactcaa agtttttgat
     1051  gatgccccca ctcggtgagg ccccttcaa gtgccatctg tttacttctc
     1101  aaatgaaaaa gaattcaggt ctgagtgtcc aggaaagggg gtgaatttca
     1151  taaccgcctg tgacagcgat gggaaggagc cacaccctc cagaggggtac
     1201  caccagcgg acaagtgggg aggaggaagt agctggcatg aagccggccc
30    1251  acccaacctc cgggagagag gaaaaggaga acacgggatg aggaggcttt
     1301  aaatagtatt tcataaaata aaaatgcca gcactcttag gaacctctca
     1351  ttcaaccgcc tagtttttgt ttaaataatt ctaatgccag aggctggggg
     1401  gcagggggcg gccagggtat gtacatgagg aggtgttta attaaacac
     1451  aaataataat taagacacac aaactgagac taaggcagaa gatgtagagc
35    1501  gggcctttga ggccctcgcg cttccaggac tgcaggcttc ctgtggcgcg
     1551  attagggctt cctcttgag aagatcagcc gcggtttgga gtggtagaaa
     1601  tctgtcatgc tgggtctgcg ccgttttcga ccctgagagt ctccagggtc
```

1651 acctggggac ccttcagcct gctcccctga gcgaggcaca aggggtacaag  
1701 acagtgcacag gtccacatgg tcttcctctg ctgtcccctg cagcagagca  
1751 ggtgaggtgc caggccgcct gcctcctccc aactcatccc ggctcgcgcg  
1801 gggccccgtg ggaaggtaga gcttgggcag gccaaaggccc cgcacacgct  
5 1851 cccaggcgaa gtcacccctcc agtggtgtct cggtgacaaa gtcgaagttc  
1901 catcgctcac gggcctcctg gatgcagccc gccattagcg catcacagtc  
1951 gcggctcagc tgctcgctgt ccactgggcc gaagaggcgg cggcaggcct  
2001 tgctgccgca tgggttctga cggacatccc cagccggttc tgacatggcg  
2051 cctgccgcag aaacacctgt gaacgcagca cacaccgcg aacacgcac  
10 2101 ctgcgggaca cgcagggaca cacgcgggca cgcttggtct ggctctgggc  
2151 cgccggcccg gggctcccctg ttgtctgccg ccgctctctc acctcctctg  
2201 agtgccctcg tgccctcggc aatccgcgcc cagctccggc tccacaagga  
2251 actgacttcg gcagc

The murine p21 sequence is provided below:

15 **SEQ ID NO. 5:**

1 gagccgagag gtgtgagccg ccgcggtgtc agagtctagg ggaattggag  
51 tcaggcgagc atccacagcg atatccagac attcagagcc acaggcacca  
101 tgtccaatcc tggatgatgtc cgacctgttc cgcacaggag caaagtgtgc  
151 cgttgtctct tcggtcccg tggacagtgc cagttgcgcc gtgattgcga  
20 201 tgcgctcatg gcgggctgtc tccaggaggc ccgagaacgg tggaaacttg  
251 acttcgtcac ggagacgccg ctggagggca acttcgtctg ggagcgcgtt  
301 cggagcctag ggctgcccaa ggtctacctg agccctgggt cccgcagccg  
351 tgacgacctg ggaggggaca agaggcccag tacttctctt gccctgtctc  
401 aggggccagc tccggaggac cacgtggcct tgctcgctgtc ttgcactctg  
25 451 gtgtctgagc ggctgaaga tccccgggt gggcccgga catctcaggg  
501 ccgaaaacgg aggcagacca gcctgacaga tttctatcac tccaagcgca  
551 gattggctct ctgcaagaga aaacctgaa gtgcccacgg gagccccgcc  
601 ctcttctgct gtgggtcagg aggcctcttc cccatcttcg gccttagccc  
651 tcaactctgt tgtcttaatt attatttgtg ttttaattta aacgtctcct  
30 701 gtatatacgc tgccctgcct ctcccagtct ccaaacttaa agttatttaa  
751 aaaaagaaca aaacaaaaca aaaaaaaccc aaacaaaac aaacctaaat  
801 tagtaggacg gtagggccct tagtgtgggg gatttctatt atgtagatta  
851 ttattattta agccccctcc aaccaagct ctgtgtttcc tataccggag  
901 gaacagtcct actgatatca acccatctgc atccgtttca cccaaccccc  
35 951 ctccccccat tccctgcctg gtcccttgcc acttcttacc tgggggtgat  
1001 cctcagacct gaatagcact ttggaaaaat gagtaggact ttggggtctc  
1051 cttgtcacct ctaaggccag ctaggatgac agtgaagcag tcacagccta

```

1101  gaacagggat ggcagttagg actcaaccgt aatatcccgga ctcttgacat
1151  tgctcagacc tgtgaagaca ggaatgggcc cactctgga tcccccttgc
1201  cactcctggg gagccacact ctctgtggg tctctgccag ctgccccctt
1251  attttgagg gttaatctgg tgatctgctg ctctttccc ccacccata
5    1301  ctccccctt tgcaggtcgg caggaggcat atctaggcac ttgcccaca
1351  gctcagtggg ctggaaggga atgtatatgc agggtagact aagtgggatt
1401  ccctggctct accttaggca gctccagtgg caacccctg cattgtgggt
1451  ctagggtggg tccttggtgg tgagacaggc ctccagagc attctatggt
1501  gtgtgggtgg gggggtgggc ttatctggga tggggacccc agttgggggt
10   1551  ctcagtgact tctccattt ctagtagca gttgtacaag gagccaggcc
1601  aagatgggtg cttgggggct aaggagctc acaggacact gagcaatggc
1651  tgatccttct cagtgttga ataccgtggg tgtcaaagca cttagtgggt
1701  ctgactccag ccccaaacat ccctgtttct gtaacatcct ggtctggact
1751  gtctaccctt agcccgacc ccaagaacat gtattgtggc tccctccctg
15   1801  tctccactca gattgtaagc gtctcacgag aagggacagc accctgcatt
1851  gtcccgagtc ctcacaccg accccaaagc tgggtgctca taaatacttc
1901  tcgatgatt

```

The antisense murine p21 sequence is provided below

**SEQ ID NO. 6:**

```

20   1    aatcatcgag aagtatttat tgagcaccag ctttggggtc ggggtgtgagg
51    actcgggaca atgcagggtg ctgtcccttc tcgtgagacg cttacaatct
101   gagtggagac agggaggagg ccacaatata tgttcttggg gtgagggtca
151   agggtagaca gtccagacca ggatgttaca gaaacaggga tgtttggggc
201   tggagtcaga cccactaagt gctttgacac ccacggtatt caacactgag
25   251   aaaggatcag ccattgctca gtgtcctgtg agctccctta gcccccaaga
301   caccatcttg gcctggctcc ttgtacaact gctactaaga aatgggagaa
351   gtcactgaga accccaactg ggggtcccat cccagataag cccaccccca
401   ccaccacaca ccatagaatg ctctgggagg cctgtctcac caccaaggac
451   ccaccctaga ccacaatgc aggggggtgc cactggagct gcctaaggta
30   501   agaccaggga atcccactta gtgtaccctg catatacatt ccttccagt
551   cactgagct gtggggcaag tgcctagata tgctcctgc cgacctgcag
601   aagggaagt atgggggtgg ggaaaagagc agcagatcac cagattaacc
651   ctccaaaata gaggggcagc tggcagagac ccacaggaga ggtgggctcc
701   ccaggagtgg caaaggggat ccagagtggg gaccattcct gtcttcacag
35   751   gtctgagcaa tgtcaagagt cgggatatta cggttgagtc ctaactgcc
801   tccctgttct aggtgtgac tgcttactg tcatcctagc tggccttaga
851   ggtgacaagg agaccccaaa gtctactca tttttccaaa gtgctattca

```

```

901   ggtctgagga tcacccccag gtaagaagtg gcaaggaacc aggcagggaa
951   tggggggagg ggggttgggt gaaacggatg cagatgggtt gatatcagta
1001  ggactgttcc tccggtatag gaaacacaga gcttgggttg ggaggggctt
1051  aaataataat aatctacata atagaaatcc cccacactaa gggccctacc
5     1101  gtcctactaa tttaggtttg ttttgttttg gttttttttt gttttgtttt
1151  gttctttttt taaataactt taagtttggg gactgggaga gggcaggcag
1201  cgtatataca ggagacgttt aaattaaaac acaaataata attaagacac
1251  acagagtgag ggctaaggcc gaagatgggg aagaggcctc ctgaccacaca
1301  gcagaagagg gcggggctcc cgtgggcact tcagggtttt ctcttgcala
10    1351  agaccaatct gcgcttgagg tgatagaaat ctgtcaggct ggctgcctc
1401  cgttttcggc cctgagatgt tccgggccc cccggggaat cttcaggccg
1451  ctcagacacc agagtgaag acagcgacaa ggccacgtgg tcctccggag
1501  ctggcccctg cagcagggca gaggaagtac tgggcctctt gtcccctccc
1551  aggtcgtcac ggctgcggga cccagggctc aggtagacct tgggcagccc
15    1601  taggctccga acgcgtcccc agacgaagtt gccctccagc ggcgtctccg
1651  tgacgaagtc aaagtccac cgttctcggg cctcctggag acagcccgcc
1701  atgagcgcat cgcaatcacg gcgcaactgc tcaactgtcca cgggaccgaa
1751  gagacaacgg cacactttgc tcctgtgcgg aacaggtcgg acatcaccag
1801  gattggacat ggtgcctgtg gctctgaatg tctggatata gctgtggatc
20    1851  tgcgcctgac tccaattccc ctagactctg acaccgcggc ggctcacacc
1901  tctcggctc

```

Of particular interest are antisense oligonucleotides that have a nucleotide sequence of 10, and more preferably 20, nucleotides within the sequence 1751-1850 or 1351-1450 of **SEQ ID NO.:6**, or of variants or fragments thereof that possess the ability to inhibit p21 expression and/or HIV replication or transmission. Such variants include oligonucleotides that are complementary to a corresponding region of the human p21 gene, or to non-human homologs as well as oligonucleotides that are composed of at least 10 of the nucleotide residues of 1751-1850 or 1351-1450 of **SEQ ID NO.: 6**. As an example, **SEQ ID NO.:7**: 5'-TGTCAGGCTGGTCTGCCTCC-3', is an antisense oligonucleotide of **SEQ ID NO.: 6** (shown underlined in **SEQ ID NO.: 6**) that possesses the ability to inhibit p21 expression and/or HIV replication or transmission. An example of a variant of this sequence is the corresponding sequence of the human p21 antisense sequence: **SEQ ID NO. 8**: TGTCATGC TGGTCTGCCG CC, shown underlined in **SEQ ID NO.:4**).

As a further example, the antisense oligonucleotide, **SEQ ID NO. 9**: 5'-ACATCACCAGGATTGGACAT-3', is fragment of **SEQ ID NO.: 6** (shown double underlined in **SEQ ID NO.: 6**) that possesses the ability to inhibit human p21 expression and/or HIV replication or transmission. An example of a variant of this sequence is the corresponding sequence of the human p21 antisense sequence: **SEQ ID NO. 10**: ACATCCCCAGCCGGTCTGACAT, shown double underlined in **SEQ ID NO.:4**).

Additional examples of preferred p21 inhibitors of the present invention include polynucleotide fragments of **SEQ ID NO.: 11** (the antisense complement of the promoter region of the p21 gene (**SEQ ID NO.:12**)) or allelic or non-human species variants thereof, as well as promoter blockers, and other transcriptional or translational repressors of the p21 gene.

**SEQ ID NO.:11**

1 accatccctt tctcacctg aaaacaggca gccaaggac aaaatagcca  
15 51 ccagcctctt ctatgccaga gctcaacatg ttgggacatg ttcctgacgg  
101 ccagaaagcc aatcagagcc acagcctgct gccaagcat gttcctggga  
151 agcaggcagc atagggatgg agggaggctc agcctggggg aacaagagtg  
201 cc

**SEQ ID NO.:12**

20 1 ggcaactcttg ttccccagc ctgagcctcc ctccatccct atgctgcctg  
51 cttcccagga acatgcttgg gcagcaggct gtggctctga ttggctttct  
101 ggccgtcagg aacatgtccc aacatgttga gctctggcat agaagaggct  
151 ggtggctatt ttgtccttgg gctgcctggt ttcagggtgag gaaggggatg  
201 gt

25 Additional examples of preferred p21 inhibitors of the present invention include protein and other non-polynucleotide inhibitors of transcription, translation of the p21 gene, inhibitory p21 mimetics, or or inhibitors of the transport or processing of the expressed p21 gene product (**SEQ ID NO.: 13**).

**SEQ ID NO.: 13:**

1 MSEFAGDVRQ NPCGSKACRR LFGPVDSEQL SRDCDALMAG CIQEARERWN  
51 FDFVTETPLE GDFAWERVRG LGLPKLYLPT GPRRGRDELG GGRRPGTSPA  
101 LLQGTAEEDH VDLSLSCTLV PRSGEQAEGS PGGPGDSQGR KRRQTSMTDF  
5 151 YHSKRRLIFS

Preferred inhibitors thus include triterpenoids, especially oleanane triterpenoids, and particularly the oleanane triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), and analogs thereof (see, for example, Stadheim, T.A. *et al.* (2002) "THE NOVEL TRITERPENOID 2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OIC ACID (CDDO) POTENTLY ENHANCES APOPTOSIS INDUCED BY TUMOR NECROSIS FACTOR IN HUMAN LEUKEMIA CELLS," J Biol Chem. 277:16448-16455; Suh, N. *et al.* (1999) "A NOVEL SYNTHETIC OLEANANE TRITERPENOID, 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID, WITH POTENT DIFFERENTIATING, ANTIPROLIFERATIVE, AND ANTI-INFLAMMATORY ACTIVITY," Cancer Res. 59:336-341). Also suitable are derivatives and salts of such compounds, for example, 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im) (Place, W.A. *et al.* (2003) "The Novel Synthetic Triterpenoid, CDDO-Imidazolidine, Inhibits Inflammatory Response and Tumor Growth in Vivo," Clinical Cancer Research 9:2798-2806).

20 Molecules that inhibit or otherwise interfere with p21 function include binding ligands of p21 protein, including antibodies, or fragments thereof that bind to p21 protein. Suitable antibodies may be derived from human antisera, from non-human mammalian origin, or may be monoclonal, recombinant, single-chain, or humanized. Antigen-binding fragments of such antibodies (e.g., Fab and F(ab)<sub>2</sub> fragments) may alternatively be employed. If desired, such administration can be  
25 provided in concert with other p21 inhibitors.

**Compositions of the Present Invention**

In one embodiment of the present invention, non-polynucleotide p21 inhibitors may be employed. Alternatively, or conjunctively, one or more of the

above-described p21 inhibitor molecules will comprise a polynucleotide or polynucleotide construct that may be administered to a recipient prior to the commencement of HIV infection, or subsequent to the onset of such infection. In accordance with the methods of the present invention, a single polynucleotide, 5 polynucleotide construct, or composition comprising a polynucleotide or polynucleotide construct containing more than one polynucleotide sequence encoding one or more molecules may be administered. Alternatively, more than one polynucleotide, polynucleotide construct, or composition comprising a polynucleotide or polynucleotide construct, each containing polynucleotide 10 sequences encoding one or more molecules may be co-administered or sequentially administered.

If the p21 inhibitor compound(s) of the present invention is/are administered as a pharmaceutical composition, such pharmaceutical composition can be formulated according to known methods for preparing pharmaceutical 15 compositions, whereby the substance to be delivered is combined with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their preparation are described, for example, in Remington's Pharmaceutical Sciences, 16<sup>th</sup> Edition, A. Osol, Ed., Mack Publishing Co., Easton, Pa. (1980), and Remington's Pharmaceutical Sciences, 19<sup>th</sup> Edition, A. R. Gennaro, Ed., Mack 20 Publishing Co., Easton, Pa. (1995).

The amount of a polynucleotide or polynucleotide construct or other p21 inhibitor included in such a composition depends on factors including the age and weight of the subject, the delivery method and route, the type of treatment desired, and the type of polynucleotide or polynucleotide construct or other p21 inhibitor 25 being administered. In general, a composition of the present invention that includes polynucleotide or polynucleotide constructs will contain from about 1 ng to about 30 mg of such polynucleotide or polynucleotide construct, more preferably, from about 100 ng to about 10 mg of such polynucleotide or polynucleotide construct. Certain preferred compositions of the present invention 30 may include about 1 ng of such polynucleotide or polynucleotide construct, about 5



ng of such polynucleotide or polynucleotide construct, about 10 ng of such  
polynucleotide or polynucleotide construct, about 50 ng of such polynucleotide or  
polynucleotide construct, about 100 ng of such polynucleotide or polynucleotide  
construct, about 500 ng of such polynucleotide or polynucleotide construct, about 1  
5 µg of such polynucleotide or polynucleotide construct, about 5 µg of such  
polynucleotide or polynucleotide construct, about 10 µg of such polynucleotide or  
polynucleotide construct, about 50 µg of such polynucleotide or polynucleotide  
construct, about 100 µg of such polynucleotide or polynucleotide construct, about  
150 µg of such polynucleotide or polynucleotide construct, about 200 µg of such  
10 polynucleotide or polynucleotide construct, about 250 µg of such polynucleotide or  
polynucleotide construct, about 300 µg of such polynucleotide or polynucleotide  
construct, about 350 µg of such polynucleotide or polynucleotide construct, about  
400 µg of such polynucleotide or polynucleotide construct, about 450 µg of such  
polynucleotide or polynucleotide construct, about 500 µg of a polynucle-otide,  
15 about 550 µg of such polynucleotide or polynucleotide construct, about 600 µg of  
such polynucleotide or polynucleotide construct, about 650 µg of such  
polynucleotide or polynucleotide construct, about 700 µg of such polynucleotide or  
polynucleotide construct, about 750 µg of such polynucleotide or polynucleotide  
construct, about 800 µg of such polynucleotide or polynucleotide construct, about  
20 850 µg of a polynucle-otide, about 900 µg of such polynucleotide or  
polynucleotide construct, about 950 µg of such polynucleotide or polynucleotide  
construct, about 1 mg of such polynucleotide or polynucleotide construct, about 5  
mg of such polynucleotide or polynucleotide construct, about 10 mg of such  
polynucleotide or polynucleotide construct, about 15 mg of such polynucleotide or  
25 polynucleotide construct, about 20 mg of such polynucleotide or polynucleotide  
construct, about 25 mg of such polynucleotide or polynucleotide construct, or  
about 30 mg of such polynucleotide or polynucleotide construct.

Nucleic acids and/or polynucleotides and/or polynucleotide constructs of  
the present invention, e.g., plasmid DNA, derivatives of plasmid DNA, mRNA,  
30 linear DNA, viral genomes, or polynucleotide fragments contained therein may be

formulated into any of the various compositions and may be used in any of the methods disclosed herein. As used herein, the term “polynucleotide fragment” refers to a polynucleotide that is either a portion of a gene, cDNA or RNA molecule, or a complement of such molecules, and which possesses a length of at least 10 nucleotide residues, at least 15 nucleotide residues, at least 20 nucleotide residues, at least 25 nucleotide residues, at least 35 nucleotide residues, at least 50 nucleotide residues, at least 75 nucleotide residues, at least at least 100 nucleotide residues, at least 150 nucleotide residues, or at least 200 nucleotide residues.

For aqueous compositions used in vivo, use of sterile pyrogen-free water is preferred. Such formulations will contain an effective amount of such polynucleotide or polynucleotide construct together with a suitable salt and/or auxiliary agent as disclosed herein, in order to prepare pharmaceutically acceptable compositions suitable for optimal administration to a vertebrate. Insoluble polynucleotides or polynucleotide constructs may be solubilized in a weak acid or weak base, and then diluted to the desired volume, for example, with an aqueous solution of the present invention. The pH of the solution may be adjusted as appropriate. In addition, a pharmaceutically acceptable additive can be used to provide an appropriate osmolarity.

As used herein a “salt” is a substance produced from the reaction between acids and bases which comprises a metal (cation) and a nonmetal (anion). Salt crystals may be “hydrated” i.e., contain one or more water molecules. Such hydrated salts, when dissolved in an aqueous solution at a certain molar concentration, are equivalent to the corresponding anhydrous salt dissolved in an aqueous solution at the same molar concentration. For the present invention, salts which are readily soluble in an aqueous solution are preferred.

The terms “saline” or “normal saline” as used herein refer to an aqueous solution of about 145 mM to about 155 mM sodium chloride, preferably about 154 mM sodium chloride. The terms “phosphate buffered saline” or PBS” refer to an aqueous solution of about 145 mM to about 155 mM sodium chloride, preferably

about 154 sodium chloride, and about 10 mM sodium phosphate, at a pH ranging from about 6.0 to 8.0, preferably at a pH ranging from about 6.5 to about 7.5, most preferably at pH 7.2.

Such compositions of the present invention may include one or more  
5 transfection facilitating materials that facilitate delivery of polynucleotides or polynucleotide constructs to the interior of a cell, and/or to a desired location within a cell. Examples of the transfection facilitating materials include, but are not limited to lipids, preferably cationic lipids; inorganic materials such as calcium phosphate, and metal (e.g., gold or tungsten) particles (e.g., “powder” type delivery  
10 solutions); peptides, including cationic peptides, targeting peptides for selective delivery to certain cells or intracellular organelles such as the nucleus or nucleolus, and amphipathic peptides, i.e. helix forming or pore forming peptides; basic proteins, such as histones; asialoproteins; viral proteins (e.g., Sendai virus coat protein); pore-forming proteins; and polymers, including dendrimers, star-  
15 polymers, “homogenous” poly-amino acids (e.g., poly-lysine, poly-arginine), “heterogenous” poly-amino acids (e.g., mixtures of lysine & glycine), co-polymers, polyvinylpyrrolidinone (PVP), and polyethylene glycol (PEG). Furthermore, those auxiliary agents of the present invention which facilitate and enhance the entry of a polynucleotide or polynucleotide construct into vertebrate  
20 cells in vivo, may also be considered “transfection facilitating materials.”

Certain embodiments of the present invention may include lipids as a transfection facilitating material, including cationic lipids (e.g., DMRIE, DOSPA, DC-Chol, GAP-DLRIE), basic lipids (e.g., steryl amine), neutral lipids (e.g., cholesterol), anionic lipids (e.g., phosphatidyl serine), and zwitterionic lipids (e.g.,  
25 DOPE, DOPC).

Examples of cationic lipids are 5-carboxyspermylglycine dioctadecylamide (DOGS) and dipalmitoyl-phosphatidylethanolamine-5-carboxy-spermylamide (DPPES). Cationic cholesterol derivatives are also useful, including {3  $\beta$ -[N-N',N'-dimethylamino)ethane]-carbomoyl}-cholesterol (DC-Chol). Dimethyldioctdecyl-

ammonium bromide (DDAB), N-(3-aminopropyl)-N,N-(bis-(2-tetradecyloxyethyl))-N-methyl-ammonium bromide (PADEMO), N-(3-aminopropyl)-N,N-(bis-(2-dodecyloxyethyl))-N-methyl-ammonium bromide (PADELO), N,N,N-tris-(2-dodecyloxy)ethyl-N-(3-amino)propyl-ammonium bromide (PATELO), and N<sub>1</sub>-(3-aminopropyl)((2-dodecyloxy)ethyl)-N<sub>2</sub>-(2-dodecyloxy)ethyl-1-piperazinaminium bromide (GALOE-BP) can also be employed in the present invention.

Non-diether cationic lipids, such as DL-1,2-dioleoyl-3-dimethylaminopropyl- $\beta$ -hydroxyethylammonium (DORI diester), 1-O-oleyl-2-oleoyl-3-dimethylaminopropyl- $\beta$ -hydroxyethylammonium (DORI ester/ether), and their salts promote in vivo gene delivery. Preferred cationic lipids comprise groups attached via a heteroatom attached to the quaternary ammonium moiety in the head group. A glycol spacer can connect the linker to the hydroxyl group.

Cationic lipids for use in certain embodiments of the present invention include DMRIE (( $\pm$ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide), and GAP-DMORIE ((+)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradeceneyloxy)-1-propanaminium bromide), as well as ( $\pm$ )-N,N-dimethyl-N-[2-(sperminecarboxamido)ethyl]-2,3-bis(dioleyloxy)-1-propaniminium pentahydrochloride (DOSPA), ( $\pm$ )-N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propaniminium bromide ( $\beta$ -aminoethyl-DMRIE or  $\beta$ AE-DMRIE) (Wheeler, et al., *Biochim. Biophys. Acta* 1280:1-11 (1996)), and ( $\pm$ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propaniminium bromide (GAP-DLRIE) (Wheeler, et al., *Proc. Natl. Acad. Sci. USA* 93:11454-11459 (1996)), which have been developed from DMRIE. Other examples of DMRIE-derived cationic lipids that are useful for the present invention are ( $\pm$ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (GAP-DDRIE), ( $\pm$ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (GAP-DMRIE), ( $\pm$ )-N-((N'-methyl)-N'-ureyl)propyl-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (GMU-DMRIE), ( $\pm$ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-

bis(dodecyloxy)-1-propanaminium bromide (DLRIE), and ( $\pm$ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis-([Z]-9-octadecenyl-oxy)propyl-1-propanaminium bromide (HP-DORIE).

A cationic lipid that may be used in concert with the p21 inhibitor  
5 polynucleotide compositions of the present invention is a “cytofectin.” As used herein, a “cytofectin” refers to a subset of cationic lipids which incorporate certain structural features including, but not limited to, a quaternary ammonium group and/or a hydrophobic region (usually with two or more alkyl chains), but which do not require amine protonation to develop a positive charge. Examples of  
10 cytofectins may be found, for example, in U.S. Patent No. 5,861,397. Cytofectins that may be used in the present invention, include DMRIE (( $\pm$ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide), GAP-DMORIE (( $\pm$ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyl-oxy)-1-propanaminium bromide), and GAP-DLRIE (( $\pm$ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide).  
15

The cationic lipid may be mixed with one or more co-lipids. The term “co-lipid” refers to any hydrophobic material which may be combined with the cationic lipid component and includes amphipathic lipids, such as phospholipids, and neutral lipids, such as cholesterol. Cationic lipids and co-lipids may be mixed or  
20 combined in a number of ways to produce a variety of non-covalently bonded macroscopic structures, including, for example, liposomes, multilamellar vesicles, unilamellar vesicles, micelles, and simple films. A preferred class of co-lipids are the zwitterionic phospholipids, which include the phosphatidylethanolamines and the phosphatidylcholines. Most preferably, the co-lipids are  
25 phosphatidylethanolamines, such as, for example, DOPE, DMPE and DPyPE. DOPE and DPyPE are particularly preferred. For immunization, the most preferred co-lipid is DPyPE, which comprises two phytanoyl substituents incorporated into the diacylphosphatidylethanolamine skeleton. The cationic lipid:co-lipid molar ratio may range from about 9:1 to about 1:9, or from about 4:1 to about 1:4, or  
30 from about 2:1 to about 1:2, or about 1:1. In order to maximize homogeneity, such

cationic lipid and co-lipid components may be dissolved in a solvent such as chloroform, followed by evaporation of the cationic lipid/co-lipid solution under vacuum to dryness as a film on the inner surface of a glass vessel (e.g., a Rotovap round-bottomed flask). Upon suspension in an aqueous solvent, the amphipathic lipid component molecules self-assemble into homogenous lipid vesicles. These lipid vesicles may subsequently be processed to have a selected mean diameter of uniform size prior to complexing with, for example, plasmid DNA according to methods known to those skilled in the art. For example, the sonication of a lipid solution is described in Felgner, P.L., *et al.* (1987) "LIPOFECTION: A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE," Proc. Natl. Acad. Sci. USA 84:7413-7417 and in U.S. Patent No. 5,264,618.

In some embodiments, such polynucleotide or polynucleotide construct(s) are combined with lipids by mixing, for example, a plasmid DNA solution and a solution of cationic lipid:co-lipid liposomes. Preferably, the concentration of each of the constituent solutions is adjusted prior to mixing such that the desired final plasmid DNA/cationic lipid:co-lipid ratio and the desired plasmid DNA final concentration will be obtained upon mixing the two solutions. For example, if the desired final solution is to be 2.5 mM sodium phosphate, the various components of the composition, e.g., plasmid DNA, cationic lipid:co-lipid liposomes, and any other desired auxiliary agents, transfection facilitating materials, or additives are each prepared in 2.5 mM sodium phosphate and then simply mixed to afford the desired complex. Alternatively, if the desired final solution is to be, e.g., 2.5 mM sodium phosphate, certain components of the composition, e.g., the auxiliary agent and/or cationic lipid:co-lipid liposomes, is prepared in a volume of water which is less than that of the final volume of the composition, and certain other components of the composition, e.g., the plasmid DNA, is prepared in a solution of sodium phosphate at a higher concentration than 2.5 mM, in a volume such that when the components in water are added to the components in the sodium phosphate solution, the final composition is in an aqueous solution of 2.5 mM sodium phosphate. For example, the plasmid DNA could be prepared in 5.0 mM sodium

phosphate at one half the final volume, the auxiliary agent and/or cationic lipid:co-lipid liposome is prepared in water at one half the final volume, and then these two elements are mixed together to produce the final composition. The cationic lipid:co-lipid liposomes are preferably prepared by hydrating a thin film of the mixed lipid materials in an appropriate volume of aqueous solvent by vortex mixing at ambient temperatures for about 1 minute. The thin films are prepared by admixing chloroform solutions of the individual components to afford a desired molar solute ratio followed by aliquoting the desired volume of the solutions into a suitable container. The solvent is removed by evaporation, first with a stream of dry, inert gas (e.g. argon) followed by high vacuum treatment.

A transfection facilitating material can be used alone or in combination with one or more other transfection facilitating materials. Two or more transfection facilitating materials can be combined by chemical bonding (e.g. covalent and ionic such as in lipidated polylysine, PEGylated polylysine) (Toncheva, V., *et al.* (1998) "NOVEL VECTORS FOR GENE DELIVERY FORMED BY SELF-ASSEMBLY OF DNA WITH POLY(L-LYSINE) GRAFTED WITH HYDROPHILIC POLYMERS," *Biochim. Biophys. Acta* 1380(3):354-368), mechanical mixing (e.g., free moving materials in liquid or solid phase such as "polylysine+cationic lipids") (Gao, X. *et al.* (1996) "POTENTIATION OF CATIONIC LIPOSOME-MEDIATED GENE DELIVERY BY POLYCATIONS," *Biochemistry* 35:1027-1036); Trubetskoy, V.S., *et al.* (1992) "CATIONIC LIPOSOMES ENHANCE TARGETED DELIVERY AND EXPRESSION OF EXOGENOUS DNA MEDIATED BY N-TERMINAL MODIFIED POLY(L-LYSINE)-ANTIBODY CONJUGATE IN MOUSE LUNG ENDOTHELIAL CELLS," *Biochem. Biophys. Acta* 1131:311-313), and aggregation (e.g., co-precipitation, gel forming such as in cationic lipids+poly-lactide co-galactide, and polylysine+gelatin).

Other hydrophobic and amphiphilic additives, such as, for example, sterols, fatty acids, gangliosides, glycolipids, lipopeptides, liposaccharides, neobees, niosomes, prostaglandins and sphingolipids, may also be included in the compositions of the present invention. In such compositions, these additives may be included in an amount between about 0.1 mol % and about 99.9 mol % (relative

to total lipid). Preferably, these additives comprise about 1-50 mol % and, most preferably, about 2-25 mol %. Preferred additives include lipopeptides, liposaccharides and steroids.

In embodiments of the present invention in which non-polynucleotide p21 inhibitors are provided, such compounds can be formulated according to known methods for preparing such pharmaceutical compositions, whereby the substance to be delivered is combined with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their preparation are described, for example, in Remington's Pharmaceutical Sciences, 16<sup>th</sup> Edition, A. Osol, Ed., Mack Publishing Co., Easton, Pa. (1980), and Remington's Pharmaceutical Sciences, 19<sup>th</sup> Edition, A. R. Gennaro, Ed., Mack Publishing Co., Easton, Pa. (1995). The amount of such compounds included in such a composition depends on factors including the age and weight of the subject, the delivery method and route, the type of treatment desired, and the type of polynucleotide or polynucleotide construct or other p21 inhibitor being administered. In general, a composition of the present invention that includes such inhibitors will contain from about 1 ng to about 30 mg, and more preferably, from about 100 ng to about 10 mg of such inhibitor. Certain preferred compositions of the present invention may include about 1 ng of such inhibitor, about 5 ng of such inhibitor, about 10 ng of such inhibitor, about 50 ng of such inhibitor, about 100 ng of such inhibitor, about 500 ng of such inhibitor, about 1 µg of such inhibitor, about 5 µg of such inhibitor, about 10 µg of such inhibitor, about 50 µg of such inhibitor, about 100 µg of such inhibitor, about 150 µg of such inhibitor, about 200 µg of such inhibitor, about 250 µg of such inhibitor, about 300 µg of such inhibitor, about 350 µg of such inhibitor, about 400 µg of such inhibitor, about 450 µg of such inhibitor, about 500 µg of a polynucleotide, about 550 µg of such inhibitor, about 600 µg of such inhibitor, about 650 µg of such inhibitor, about 700 µg of such inhibitor, about 750 µg of such inhibitor, about 800 µg of such inhibitor, about 850 µg of a polynucleotide, about 900 µg of such inhibitor, about 950 µg of such inhibitor, about 1 mg of such inhibitor, about 5 mg of such inhibitor, about 10 mg of such inhibitor, about 15 mg of such inhibitor, about 20



mg of such inhibitor, about 25 mg of such inhibitor, or about 30 mg of such inhibitor.

Such compositions may be formulated into any of the various compositions and may be used in any of the methods disclosed herein. For aqueous  
5 compositions used in vivo, use of sterile pyrogen-free water is preferred. Such formulations will contain an effective amount of such inhibitor together with a suitable salt and/or auxiliary agent as disclosed herein, in order to prepare pharmaceutically acceptable compositions suitable for optimal administration to a vertebrate. Insoluble inhibitors may be solubilized in a weak acid or weak base,  
10 and then diluted to the desired volume, for example, with an aqueous solution of the present invention. The pH of the solution may be adjusted as appropriate. In addition, a pharmaceutically acceptable additive can be used to provide an appropriate osmolarity. Alternatively, lipids and lipid vehicles (as discussed above) may be used to facilitate the inhibitor administration. Other hydrophobic  
15 and amphiphilic additives, such as, for example, sterols, fatty acids, gangliosides, glycolipids, lipopeptides, liposaccharides, neobees, niosomes, prostaglandins and sphingolipids, may also be included in such compositions of the present invention. In such compositions, these additives may be included in an amount between about 0.1 mol % and about 99.9 mol % (relative to total lipid). Preferably, these  
20 additives comprise about 1-50 mol % and, most preferably, about 2-25 mol %. Preferred additives include lipopeptides, liposaccharides and steroids.

#### **Pharmaceutical Compositions**

The pharmaceutical composition of the present invention may be in the form of an emulsion, gel, solution, suspension, etc. In addition, the pharmaceutical  
25 composition can also contain pharmaceutically acceptable additives including, for example, diluents, binders, stabilizers, and preservatives. Administration of pharmaceutically acceptable salts of the polynucleotides described herein is preferred. Such salts can be prepared from pharmaceutically acceptable non-toxic bases including organic bases and inorganic bases. Salts derived from inorganic

bases include sodium, potassium, lithium, ammonium, calcium, magnesium, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, basic amino acids, and the like. Preferred salts include but are not limited to sodium phosphate, sodium  
5 acetate, sodium bicarbonate, sodium sulfate, sodium pyruvate, potassium phosphate, potassium acetate, potassium bicarbonate, potassium sulfate, potassium pyruvate, disodium DL- $\alpha$ -glycerol-phosphate, and disodium glucose-6-phosphate. “Phosphate” salts of sodium or potassium can be either the monobasic form, e.g.,  $\text{NaHPO}_4$ , or the dibasic form, e.g.,  $\text{Na}_2\text{HPO}_4$ , but a mixture of the two, resulting in  
10 a desired pH, is most preferred. The most preferred salts are sodium phosphate or potassium phosphate. As used herein, the terms “sodium phosphate” or “potassium phosphate,” refer to a mixture of the dibasic and monobasic forms of each salt to present at a given pH.

Additional embodiments of the present invention are drawn to  
15 pharmaceutical compositions comprising one or more p21 inhibitor molecules and an auxiliary agent. The present invention is further drawn to methods to use such compositions, methods of making such compositions, and pharmaceutical kits. As used herein, an “auxiliary agent” is a substance included in a composition for its ability to enhance, relative to a composition which is identical except for the  
20 inclusion of the auxiliary agent, the effectiveness of a p21 inhibitor molecule. Auxiliary agents of the present invention include nonionic, anionic, cationic, or zwitterionic surfactant or detergents, with nonionic, anionic, cationic, or zwitterionic surfactant or detergents, with nonionic surfactant or detergents being preferred, chelators, DNase inhibitors, agents that aggregate or condense nucleic  
25 acids, emulsifying or solubilizing agents, wetting agents, gel-forming agents, and buffers.

Suitable auxiliary agents include non-ionic detergents and surfactant such as poloxaners. Poloxamers are a series of non-ionic surfactant that are block copolymers of ethylene oxide and propylene oxide. The poly(oxyethylene)  
30 segment is hydrophilic and the poly(oxypropylene) segment is hydrophobic. The

physical forms are liquids, pastes or solids. The molecular weight ranges from 1000 to greater than 16000. The basic structure of a poloxamer is HO--  
[CH<sub>2</sub>CH<sub>2</sub>O]<sub>x</sub>--[CH<sub>2</sub>CHO(CH<sub>3</sub>)]<sub>y</sub>--[CH<sub>2</sub>CH<sub>2</sub>O]<sub>x</sub>--H, where x and y represent  
repeating units of ethylene oxide and propylene oxide respectively. Thus, the  
5 propylene oxide (PO) segment is sandwiched between two ethylene oxide (EO)  
segments, (EO--PO--EO). The number of x's and y's distinguishes individual  
poloxamers. If the ethylene oxide segment is sandwiched between two propylene  
oxide segments, (PO--EO--PO), then the resulting structure is a reverse poloxamer.  
The basic structure of a reverse poloxamer is HO--[CH(CH<sub>3</sub>)CH<sub>2</sub>O]<sub>x</sub>--  
10 [CH<sub>2</sub>CH<sub>2</sub>O]<sub>y</sub>--[CH<sub>2</sub>CH--HO(CH<sub>3</sub>)]<sub>x</sub>--H.

Poloxmers that may be used in concert with the methods and compositions  
of the present invention include, but are not limited to commercially available  
poloxamers such as Pluronic® L121 (avg. MW:4400), Pluronic® L101 (avg.  
MW:3800), Pluronic® L81 (avg. MW:2750), Pluronic® L61 (avg. MW:2000),  
15 Pluronic® L31 (avg. MW: 1100), Pluronic® L122 (avg. MW:5000), Pluronic®  
L92 (avg. MW:3650), Pluronic® L72 (avg. MW:2750), Pluronic® L62 (avg.  
MW:2500), Pluronic® L42 (avg. MW:1630), Pluronic® L63 (avg. MW:2650),  
Pluronic® L43 (avg. MW: 1850), Pluronic® L64 (avg. MW:2900), Pluronic® L44  
(avg. MW:2200), Pluronic® L35 (avg. MW:1900), Pluronic® P123 (avg.  
20 MW:5750), Pluronic® P103 (avg. MW:4950), Pluronic® P104 (avg. MW:5900),  
Pluronic® P84 (avg. MW:4200), Pluronic® P105 (avg. MW:6500), Pluronic® P85  
(avg. MW:4600), Pluronic® P75 (avg. MW:4150), Pluronic® P65 (avg.  
MW:3400), Pluronic® F127 (avg. MW: 12600), Pluronic® F98 (avg. MW:  
13000), Pluronic® F87 (avg. MW:7700), Pluronic® F77 (avg. MW:6600),  
25 Pluronic® F 108 (avg. MW: 14600), Pluronic® F98 (avg. MW: 13000), Pluronic®  
F88 (avg. MW:11400), Pluronic® F68 (avg. MW:8400), and Pluronic® F38 (avg.  
MW:4700).

Reverse poloxamers of the present invention include, but are not limited to  
Pluronic® R31R1 (avg. MW:3250), Pluronic® R 25R1 (avg. MW:2700),  
30 Pluronic® R17R1 (avg. MW:1900), Pluronic® R31R2 (avg. MW:3300),

Pluronic® R25R2 (avg. MW:3100), Pluronic® R17R2 (avg. MW:2150),  
Pluronic® R12R3 (avg. MW:1800), Pluronic® R31R4 (avg. MW:4150), Pluronic®  
R25R4 (avg. MW:3600), Pluronic® R22R4 (avg. MW:3350), Pluronic® R17R4  
(avg. MW:3650), Pluronic® R25R5 (avg. MW:4320), Pluronic® R10R5 (avg.  
5 MW:1950), Pluronic® R25R8 (avg. MW:8850), Pluronic® R17R8 (avg.  
MW:7000), Pluronic® R10R8 (avg. MW:4550).

Other commercially available poloxamers include compounds that are  
block copolymer of polyethylene and polypropylene glycol such as Synperonic®  
L121, Synperonic® L122, Synperonic® P104, Synperonic® P105, Synperonic®  
10 P123, Synperonic® P85, and Synperonic® P94; and compounds that are  
nonylphenyl polyethylene glycol such as Synperonic® NP10, Synperonic® NP30,  
and Synperonic® NP5.

Suitable auxiliary agents include non-ionic detergents and surfactants such  
as Pluronic® F68, Pluronic® F77, Pluronic® F108, Pluronic® F127, Pluronic®  
15 P65, Pluronic® P85, Pluronic® P103, Pluronic® P104, Pluronic® P105,  
Pluronic® P123, Pluronic® L31, Pluronic® L43, Pluronic® L44, Pluronic® L61,  
Pluronic® L62, Pluronic® L64, Pluronic® L81, Pluronic® L92, Pluronic® L101,  
Pluronic® L121, Pluronic® R17R4, Pluronic® R25R4, Pluronic® R25R2,  
IGEPAL CA 630®, NONIDET NP-40, Nonidet® P40, Tween-20®, Tween-80®,  
20 Triton X-100®, Triton X-114.TM., Thesit®; the anionic detergent sodium dodecyl  
sulfate (SDS); the sugar stachyose; the condensing agent DMSO; and the  
chelator/DNAse inhibitor EDTA. Even more preferred are the auxiliary agents  
Nonidet® P40, Triton X-100®, Pluronic® F68, Pluronic® F77, Pluronic® F108,  
Pluronic® P65, Pluronic® P103, Pluronic® L31, Pluronic® L44, Pluronic® L61,  
25 Pluronic® L64, Pluronic® L92, Pluronic® R17R4, Pluronic® R25R4 and  
Pluronic® R25R2. Most preferred auxiliary agent is Pluronic® R25R2.

Optimal concentrations of auxiliary agents of the present invention are  
disclosed in U.S. Patent Application Publication No. 20020019358 and PCT  
Publication WO0180897A3. For example, in certain embodiments,

pharmaceutical compositions of the present invention comprise about 5 ng to about 30 mg of a suitable polynucleotide or a polynucleotide construct, and/or a non-polynucleotide p21 inhibitor, and about 0.001% (w/v) to about 2.0% (w/v) of Pluronic® R 25R4, preferably about 0.002% (w/v) to about 1.0% (w/v) of Pluronic® R 25R4, more preferably about 0.01% (w/v) to about 0.01% (w/v) of Pluronic® R 25R4, with about 0.01% (w/v) of Pluronic® R 25R4 being the most preferred; about 0.001% (w/v) to about 2.0% (w/v) of Pluronic® R 25R2, preferably about 0.001% (w/v) to about 1.0% (w/v) of Pluronic® R 25R2, more preferably about 0.001% (w/v) to about 0.1% (w/v) of Pluronic® R 25R2, with about 0.01% (w/v) of Pluronic® R 25R2 being the most preferred.

#### **Administration Of The Pharmaceutical Compositions Of The Present Invention**

The pharmaceutical compositions of the present invention may be administered by any suitable means, for example, inhalation, or interdermally, intracavity (e.g., oral, vaginal, rectal, nasal, peritoneal, ventricular, or intestinal), intradermally, intramuscularly, intranasally, intraocularly, intraperitoneally, intrarectally, intratracheally, intravenously, orally, subcutaneously, transdermally, or transmucosally (i.e., across a mucous membrane) in a dose effective for the production of neutralizing antibody and resulting in protection from infection or disease. The present pharmaceutical compositions can generally be administered in the form of a spray for intranasal administration, or by nose drops, inhalants, swabs on tonsils, or a capsule, liquid, suspension or elixirs for oral administration. The pharmaceutical compositions may be in the form of single dose preparations or in multi-dose flasks. Reference is made to Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., Osol (ed.) (1980).

Administration can be into one or more tissues including but not limited to muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, e.g., myocardium, endocardium, and pericardium; lymph nodes, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, or connective tissue. Furthermore, in the methods of

the present invention, the pharmaceutical compositions may be administered to any internal cavity of a mammal, including, but not limited to, the lungs, the mouth, the nasal cavity, the stomach, the peritoneal cavity, the intestine, any heart chamber, veins, arteries, capillaries, lymphatic cavities, the uterine cavity, the vaginal cavity, the rectal cavity, joint cavities, ventricles in brain, spinal canal in spinal cord, and the ocular cavities. Any mode of administration can be used so long as the mode results prophylactic or therapeutic efficacy. Methods to detect such a response include serological methods, e.g., western blotting, staining tissue sections by immunohistochemical methods, and measuring the activity of the polypeptide.

Pharmaceutical DNA compositions and methods of their manufacture and delivery that may be used in accordance with the present invention are disclosed in US Patents Nos. 5,589,466; 5,620,896; 5,641,665; 5,703,055; 5,707,812; 5,846,946; 5,861,397; 5,891,718; 6,022,874; 6,147,055; 6,214,804; 6,228,844; 6,399,588; 6,413,942; 6,451,769, European Patent Documents EP1165140A2; EP1006796A1 and EP0929536A1; and PCT Patent Publications WO00/57917; WO00/73263; WO01/09303; WO03/028632; WO94/29469; WO95/29703; and WO98/14439.

Administration may be by needle injection, catheter infusion, biolistic injectors, particle accelerators (e.g., "gene guns" or pneumatic "needleless" injectors) Med-E-Jet (Vahlsing, H., *et al.* (1994) "IMMUNIZATION WITH PLASMID DNA USING A PNEUMATIC GUN," J. Immunol. Methods 171:11-22), Pigjet (Schrijver, R.S. *et al.* (1997) "IMMUNIZATION OF CATTLE WITH A BHV1 VECTOR VACCINE OR A DNA VACCINE BOTH CODING FOR THE G PROTEIN OF BRSV," Vaccine 15:1908-1916), Biojector (Davis, H.L. *et al.* (1994) "DIRECT GENE TRANSFER IN SKELETAL MUSCLE: PLASMID DNA-BASED IMMUNIZATION AGAINST THE HEPATITIS B VIRUS SURFACE ANTIGEN," Vaccine 12:1503-1509; Gramzinski, R., *et al.* (1998) "IMMUNE RESPONSE TO A HEPATITIS B DNA VACCINE IN AOTUS MONKEYS: A COMPARISON OF VACCINE FORMULATION, ROUTE, AND METHOD OF ADMINISTRATION," Mol Med 4:109-118), AdvantaJet (Lindmayer, I., *et al.* (1986) "DEVELOPMENT OF NEW JET INJECTOR FOR INSULIN THERAPY," Diabetes Care

9:294-297), Medi-jector (Martins, J.K. *et al.* (1979) "MEDIJECTOR--A NEW METHOD OF CORTICOSTEROID-ANESTHETIC DELIVERY," J. Occup. Med. 21:821-824), gelfoam sponge depots, other commercially available depot materials (e.g., hydrogels), osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid  
5 (tablet or pill) pharmaceutical formulations, topical skin creams, and decanting, use of polynucleotide coated suture (Qin, J.Y. *et al.* (1999) "GENE SUTURE--A NOVEL METHOD FOR INTRAMUSCULAR GENE TRANSFER AND ITS APPLICATION IN HYPERTENSION THERAPY," Life Sciences 65:2193-2203) or topical applications during surgery.

10           Thus, in one embodiment, administration is into muscle tissue, i.e., skeletal muscle, smooth muscle, or myocardium. Most preferably, the muscle is skeletal muscle. For polynucleotide constructs in which the polynucleotide or polynucleotide construct is DNA, the DNA can be operably linked to a cell-specific promoter that directs substantial transcription of the DNA only in  
15 predetermined cells. In certain embodiments, a polynucleotide construct, or composition comprising an polynucleotide or polynucleotide construct, is delivered to any tissue including, but not limited to those disclosed herein, such that the polynucleotide or polynucleotide construct is free from association with liposomal formulations and charged lipids. Alternatively, the polynucleotide, polynucleotide  
20 construct, or composition is delivered to a tissue other than brain or nervous system tissue, for example, to muscle, skin, or blood, in any composition as described herein.

          Preferably, the pharmaceutical composition is delivered to the interstitial space of a tissue. "Interstitial space" comprises the intercellular, fluid,  
25 mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels.

Nucleic acid pharmaceutical compositions, preferably in the form of plasmid DNA, may be administered (especially by injection) into tissue and voltage pulses applied between electrodes disposed in the tissue, thus applying electric fields to cells of the tissue. The electrically-mediated enhancement covers administration using either iontophoresis or electroporation *in vivo*. Suitable techniques of electroporation and iontophoresis are provided by Singh, J. et al. (1989) "TRANSDERMAL DELIVERY OF DRUGS BY IONTOPHORESIS: A REVIEW," Drug Des. Deliv. 4:1-12; Theiss, U. et al. (1991) "IONTOPHORESIS--IS THERE A FUTURE FOR CLINICAL APPLICATION?," Methods Find. Exp. Clin. Pharmacol. 13:353-359; Singh and Maibach (1993) "TOPICAL IONTOPHORETIC DRUG DELIVERY IN VIVO: HISTORICAL DEVELOPMENT, DEVICES AND FUTURE PERSPECTIVES," Dermatology. 187:235-238; Singh, P. et al. (1994) "IONTOPHORESIS IN DRUG DELIVERY: BASIC PRINCIPLES AND APPLICATIONS," Crit. Rev. Ther. Drug Carrier Syst. 11:161-213; Su, Y. et al. (1994) "SPHINGOSINE 1-PHOSPHATE, A NOVEL SIGNALING MOLECULE, STIMULATES DNA BINDING ACTIVITY OF AP-1 IN QUIESCENT SWISS 3T3 FIBROBLASTS," J. Pharm. Sci. 83:12-17; Costello, C.T. et al. (1995) "IONTOPHORESIS: APPLICATIONS IN TRANSDERMAL MEDICATION DELIVERY," Phys. Ther. 75:554-563; Howard, J.p. et al. (1995) "EFFECTS OF ALTERNATING CURRENT IONTOPHORESIS ON DRUG DELIVERY," Arch. Phys. Med. Rehabil. 76:463-466; Kassan, D.G. et al. (1996) "PHYSICAL ENHANCEMENT OF DERMATOLOGIC DRUG DELIVERY: IONTOPHORESIS AND PHONOPHORESIS," J. Amer. Acad. Dermatol. 34:657-666; Riviere et al. (1997) "ELECTRICALLY-ASSISTED TRANSDERMAL DRUG DELIVERY," Pharm. Res. 14:687-697; Zempsky, W.T. et al. (1998) "IONTOPHORESIS: NONINVASIVE DRUG DELIVERY," Amer. J. Anesthesiol. 25:158-162; Muramatsu, T. et al. (1998) "IN VIVO ELECTROPORATION: A POWERFUL AND CONVENIENT MEANS OF NONVIRAL GENE TRANSFER TO TISSUES OF LIVING ANIMALS," Int. J. Mol. Med. 1:55-62; Garrison J. (1998) "IONTOPHORESIS: AN ALTERNATIVE DRUG-DELIVERY SYSTEM," Med. Device Technol. 9:32-36; Banga A.K. et al. (1998) "ASSESSING THE POTENTIAL OF SKIN ELECTROPORATION FOR THE DELIVERY OF PROTEIN- AND GENE-BASED DRUGS," Trends Biotechnol. 16:408-412; Banga A.K. et al. (1999)



“IONTOPHORESIS AND ELECTROPORATION: COMPARISONS AND CONTRASTS,” *Int. J. Pharm.* 179:1-19; Neumann E. *et al.* (1999) “FUNDAMENTALS OF ELECTROPORATIVE DELIVERY OF DRUGS AND GENES,” *Bioelectrochem. Bioenerg.* 48:3-16; and Heiser, W.C. (2000) “OPTIMIZING ELECTROPORATION CONDITIONS FOR THE TRANSFORMATION OF MAMMALIAN CELLS,” *Methods Mol. Biol.* 130:117-134.

The nature of the electric field generated in accordance with such methods is determined by the nature of the tissue, the size of the selected tissue and its location. The use of insufficient or excessive field strength is to be avoided. As used herein, a field strength is excessive if it results in the lysing of cells. A field strength is insufficient if it results in a reduction of efficacy of 90% relative to the maximum efficacy obtainable. The electrodes may be mounted and manipulated in many ways known in the art. The waveform of the electrical signal provided by the pulse generator can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train. The waveform, electric field strength and pulse duration are dependent upon the type of cells and the DNA that are to enter the cells via electrical-mediated delivery and thus are determined by those skilled in the art in consideration of these criteria. Any number of known devices may be used for delivering polynucleotides and generating the desired electric field. Examples of suitable devices include, but are not limited to, a single needle probe, a bipolar probe and a combination needle and plate probe. Alternatively, methods such as continuous-flow electroporation may be employed (See, U.S. Patents Nos. 6,485,961; 6,090,617; 6,074,605; 5,720,921; 5,612,207; and 5,098,843).

The compositions of the present invention can be lyophilized to produce pharmaceutical compositions in a dried form for ease in transportation and storage. The pharmaceutical compositions of the present invention may be stored in a sealed vial, ampule or the like. In the case where the pharmaceutical composition is in a dried form, the composition is dissolved or suspended (e.g., in sterilized distilled water) before administration. An inert carrier such as saline or phosphate

buffered saline or any such carrier in which the pharmaceutical compositions has suitable solubility, may be used.

Further, the pharmaceutical compositions may be prepared in the form of a mixed composition that contains one or more additional constituents so long as such additional constituents do not interfere with the effectiveness of the p21 inhibitor and the side effects and adverse reactions are not increased additively or synergistically. The pharmaceutical compositions of the present invention can be associated with chemical moieties which may improve the composition's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the pharmaceutical compositions, eliminate or attenuate any undesirable side effect of the pharmaceutical compositions, etc. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedures for coupling such moieties to a molecule are well known in the art.

Determining an effective amount of a composition depends upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the subject, the precise condition requiring treatment and its severity, and the route of administration. Based on the above factors, determining the precise amount, number of doses, and timing of doses are within the ordinary skill in the art and will be readily determined by the attending physician or veterinarian.

In one embodiment, the pharmaceutical compositions of the present invention are administered free from association with liposomal formulations, charged lipids, or transfection-facilitating viral particles. In another embodiment, the compositions of the present invention are administered free from association with any delivery vehicle now known in the art that can facilitate entry into cells.

As used herein, "ex vivo" cells are cells into which the pharmaceutical compositions is introduced, for example, by transfection, lipofection, electroporation, bombardment, or microinjection. The cells containing the pharmaceutical compositions are then administered in vivo into mammalian tissue

- (see, for example, see Beldegrun, A., *et al.* (1993) "HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES," J. Natl. Cancer Inst. 85: 207-216; Ferrantini, M. *et al.* (1993) "ALPHA 1-INTERFERON GENE TRANSFER INTO
- 5 METASTATIC FRIEND LEUKEMIA CELLS ABROGATED TUMORIGENICITY IN IMMUNOCOMPETENT MICE: ANTITUMOR THERAPY BY MEANS OF INTERFERON-PRODUCING CELLS," Cancer Research 53:1107-1112; Ferrantini, M. *et al.* (1994) "IFN-ALPHA 1 GENE EXPRESSION INTO A METASTATIC MURINE ADENOCARCINOMA (TS/A) RESULTS IN CD8<sup>+</sup> T CELL-MEDIATED TUMOR
- 10 REJECTION AND DEVELOPMENT OF ANTITUMOR IMMUNITY. COMPARATIVE STUDIES WITH IFN-GAMMA-PRODUCING TS/A CELLS," J. Immunology 153:4604-4615; Kaido, T. *et al.* (1995) "IFN-ALPHA 1 GENE TRANSFECTION COMPLETELY ABOLISHES THE TUMORIGENICITY OF MURINE B16 MELANOMA CELLS IN ALLOGENEIC DBA/2 MICE AND DECREASES THEIR TUMORIGENICITY IN SYNGENEIC
- 15 C57BL/6 MICE," Int. J. Cancer 60: 221-229; Ogura, H. *et al.* (1990) "IMPLANTATION OF GENETICALLY MANIPULATED FIBROBLASTS INTO MICE AS ANTITUMOR ALPHA-INTERFERON THERAPY," Cancer Research 50:5102-5106; Santodonato, L. *et al.* (1996) "CURE OF MICE WITH ESTABLISHED METASTATIC FRIEND LEUKEMIA CELL TUMORS BY A COMBINED THERAPY WITH TUMOR CELLS
- 20 EXPRESSING BOTH INTERFERON-ALPHA 1 AND HERPES SIMPLEX THYMIDINE KINASE FOLLOWED BY GANCICLOVIR," Human Gene Therapy 7:1-10; Santodonato, L., *et al.* (1997) "LOCAL AND SYSTEMIC ANTITUMOR RESPONSE AFTER COMBINED THERAPY OF MOUSE METASTATIC TUMORS WITH TUMOR CELLS EXPRESSING IFN-ALPHA AND HSVTK: PERSPECTIVES FOR THE GENERATION OF
- 25 CANCER VACCINES," Gene Therapy 4:1246-1255; and Zhang, J.F. *et al.* (1996) "GENE THERAPY WITH AN ADENO-ASSOCIATED VIRUS CARRYING AN INTERFERON GENE RESULTS IN TUMOR GROWTH SUPPRESSION AND REGRESSION," Cancer Gene Therapy 3:31-38.

In the "local delivery" embodiment of the present invention, a

30 pharmaceutical composition is administered *in vivo*, such that the p21 inhibitor is

incorporated into the local cells at the site of administration. The pharmaceutical compositions can be administered either within *ex vivo* cells or free of *ex vivo* cells or *ex vivo* cellular material. Preferably, the polynucleotide construct is administered free of *ex vivo* cells or *ex vivo* cellular material.

5           The pharmaceutical compositions can be solubilized in a buffer prior to administration. Suitable buffers include, for example, phosphate buffered saline (PBS), normal saline, Tris buffer, and sodium phosphate vehicle (100-150 mM preferred). Insoluble polynucleotides can be solubilized in a weak acid or base, and then diluted to the desired volume with a neutral buffer such as PBS. The pH of  
10       the buffer is suitably adjusted, and moreover, a pharmaceutically acceptable additive can be used in the buffer to provide an appropriate osmolarity within the lipid vesicle. Preferred salt solutions and auxiliary agents are disclosed herein.

          A systemic delivery embodiment is particularly preferred for treating non-localized disease conditions. A local delivery embodiment can be particularly  
15       useful for treating disease conditions that might be responsive to high local concentration. When advantageous, systemic and local delivery can be combined. U.S. Patents Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and PCT publication WO94/29469 provide methods for delivering compositions comprising naked DNA, or DNA cationic lipid complexes to mammals.

20           Compositions used in of the present invention can be formulated according to known methods. Suitable preparation methods are described, for example, in Remington's Pharmaceutical Sciences, 16<sup>th</sup> Edition, A. Osol, ed., Mack Publishing Co., Easton, Pa. (1980), and Remington's Pharmaceutical Sciences, 19<sup>th</sup> Edition, A. R. Gennaro, ed., Mack Publishing Co., Easton, Pa. (1995), both of which are  
25       incorporated herein by reference in their entirety. Although the composition is preferably administered as an aqueous solution, it can be formulated as an emulsion, gel, solution, suspension, lyophilized form, or any other form known in the art. According to the present invention, if the composition is formulated other than as an aqueous solution, it will require resuspension in an aqueous solution

prior to administration. In addition, the composition may contain pharmaceutically acceptable additives including, for example, diluents, binders, stabilizers, and preservatives.

5 The present invention also provides kits for use in treating HIV infection comprising an administration means and a container means containing a pharmaceutical composition of the present invention. Preferably, the container in which the composition is packaged prior to use will comprise a hermetically sealed container enclosing an amount of the lyophilized formulation or a solution containing the formulation suitable for a pharmaceutically effective dose thereof,  
10 or multiples of an effective dose. The composition is packaged in a sterile container, and the hermetically sealed container is designed to preserve sterility of the pharmaceutical formulation until use. Optionally, the container can be associated with administration means and/or instruction for use.

15 The present invention also provides kits for use in diagnosing West Nile Fever comprising one or more container means containing a WN polynucleotide, a polynucleotide capable of hybridizing with a WN polynucleotide, and/or a polypeptide encoded by such polynucleotides.

20 Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

**Example 1**  
**Materials and Methods**  
**For The Analysis Of Temporal Events**  
25 **Associated With The Initial Virus-Macrophage Encounter**

**A. Purification Of Human Monocytes By Counterflow Centrifugal Elutriation**

Human peripheral blood cells are obtained by leukapheresis from normal volunteers in the Department of Transfusion Medicine at the National Institutes of

Health (Bethesda, Maryland) and diluted in endotoxin-free PBS without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  (BioWhittaker, Walkersville, Maryland) for density sedimentation. The monocytes in the mononuclear cell layer are purified by counterflow centrifugal elutriation within 4 hr after leukapheresis (Wahl, S.M. *et al.* (1984) "ISOLATION OF HUMAN MONONUCLEAR CELL SUBSETS BY COUNTERFLOW CENTRIFUGAL ELUTRIATION (CCE). II. FUNCTIONAL PROPERTIES OF B-LYMPHOCYTE-, T-LYMPHOCYTE-, AND MONOCYTE-ENRICHED FRACTIONS. *Cell Immunol* 85:384-395).

10                    **B.        HIV-1 Infection Of Human Monocyte-Derived Macrophages**

Monocytes are plated in 6 well plates (Corning Costar Corporation, Cambridge, Massachusetts), at  $6 \times 10^6$  cells/well or in Lab-Tek chamber slides (Naperville, Illinois) at  $1.5 \times 10^6$ /chamber in Dulbecco's modified Eagle's medium (DMEM) with 2 mM L-glutamine and 10  $\mu\text{g}/\text{ml}$  gentamicin (BioWhittaker). After adherence (4-6 hr at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ ), 10% human AB-serum (Sigma, St. Louis, Missouri) is added to the culture medium. Cells are cultured 7 days to allow differentiation into macrophages before being infected with HIV-1<sub>BaL</sub>  $\text{TCID}_{50} = 1000\text{-}5000$  (Advanced Biotechnologies Inc., Columbia, Maryland) for 90 minutes at  $37^\circ\text{C}$ . The levels of endotoxin are below the limit of detection in virus preparations. Unbound virus is removed by washing the cells with media and refeeding with complete DMEM containing 10% human serum. Control populations of adherent macrophages are mock-infected and cultured in parallel. Every 3 to 4 days, half the medium is removed for virus assay and replaced with fresh complete medium for two weeks. Supernatant p24 antigen is assayed using the p24 core profile enzyme-linked immunosorbent assay (ELISA) kit (Perkin-Elmer Life Sciences, Wilmington, Delaware). As described below, in certain experiments, macrophages are pre-treated with 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) or a CDDO analog (di-CDDO) for 45 minutes prior to exposure to HIV-1. Additionally, macrophages are treated with p21 anti-sense phosphorothioate oligonucleotides:

**SEQ ID NO. 7:** 5'-TGTCAGGCTGGTCTGCCTCC-3'(oligo 1), and

**SEQ ID NO. 9:** 5'-ACATCACCAGGATTGGACAT-3' (oligo 2)

or negative control oligonucleotide:

**SEQ ID NO. 14:** 5'-TGGATCCGACATGTCAGA-3' (oligo 3)

5 (sequence obtained from Dr. Argyrios N. Theofilopoulos, The Scripps Research Institute, La Jolla, California) after HIV-1 infection and at the time of refeeding the cultures and tested for viral replication at day 12. **SEQ ID NOS. 7 and 9** are derived from the murine p21 antisense sequence, yet are effective in inhibiting human p21 expression and the replication and transmission of HIV.

10 **C. Northern blot Analysis and RNase Protection Assay (RPA)**

Total cellular RNA is extracted from adherent control or infected monocytes with the RNeasy minikit (Qiagen, Valencia, California) and analyzed by northern blot (Wahl, S.M. *et al.* (1998) "MYCOBACTERIUM AVIUM COMPLEX  
15 AUGMENTS MACROPHAGE HIV-1 PRODUCTION AND INCREASES CCR5 EXPRESSION. Proc Natl Acad Sci U S A 95:12574-12579) using an HIV-full length probe (NIH AIDS Research and Reference Reagent Program) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (Gibco BRL, Gaithersburg, Maryland). For the RPA 3 µg of RNA is evaluated using the hStress tRiboquant  
20 Multi-Probe RPA system (BD Pharmingen, San Diego, California) and densities are normalized to the GAPDH gene using ImageQuant (Molecular Dynamics, Sunnyvale, California)

**D. cDNA Expression Array**

The Atlas human cDNA Expression Array 1.2 I (Clontech, Palo Alto, California) (catalog # 7850-1) is performed using 5 µg of DNase digested total  
25 RNA as described by Greenwell-Wild, T. *et al.*. (2002) "MYCOBACTERIUM AVIUM INFECTION AND MODULATION OF HUMAN MACROPHAGE GENE EXPRESSION." J

Immunol 169:6286-6297. Gene expression in infected cells is compared with the corresponding control population from the same donor expressed as a ratio (fold change) after normalization to housekeeping genes. A total of seven different donors are analyzed.

5           **E.       Transmission Electron Microscopy (TEM)**

Gluteraldehyde-fixed uninfected and infected cells are postfixed in OsO<sub>4</sub> dehydrated through graded ethanol and propylene oxide, embedded in Spurr's epoxy, and thick-and thin-sectioned. Thin sections are placed on copper grids, stained with uranyl acetate and lead citrate, and viewed in a Zeiss EM10  
10   microscope (LEO Electron Microscope; Oberkochen, Germany).

**F.       Immunofluorescence microscopy**

Uninfected and HIV-1 infected macrophages that have been cultured for twelve days are washed twice with PBS, fixed with 2% paraformaldehyde in PBS, washed and incubated in 100 mM glycine in PBS for 20 min, followed by 0.5%  
15   Triton-X-100 for 10 min and rinsed with PBS. Cells are then labeled with rabbit anti-p21 antibody at 5 µg/ml (Santa Cruz Biotechnology, Santa Cruz, California) in PBS containing 5% donkey serum (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pennsylvania) for 1 hr, washed extensively, then incubated with  
20   Texas-Red conjugated secondary antibody at 3 µg/ml at room temperature (Molecular Probes, Eugene, Oregon.). Non-specific background is determined using an irrelevant rabbit isotype control antibody and secondary antibody alone at the same concentrations above. Images are captured using a Leica TCS-4D confocal microscope system with a Kr-Ar laser on a DMR upright microscope using a 40x, 1.0 numerical aperture objective. Fluorescence intensity analysis is  
25   performed using confocal microscopy and Metamorph analysis (Universal Imaging, Downingtown, Pennsylvania).



### **G. Immunoprecipitation and Western Blot Analysis**

Whole cell lysates are generated using a lysis buffer that consisted of 1% Nonidet P-40, 150mM NaCl, 20mM Tris-HCl (pH, 7.5), 10mM NaF, 10mM NaPPi, 2.5 nM EDTA, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 0.2 mM 3, 4 dicloroisocoumarin, 1mM phenylmethylsulfonyl fluoride, 100ug/ml chymostatin and 1X complete protease inhibitor (BoehringerMannheim, Indianapolis, IN). CDKN1A is immunoprecipitated from cell lysates using an anti-CDKN1A antibody conjugated to agarose (Santa Cruz Biotechnology) and incubated with constant rotation at 4<sup>0</sup>C for 2 hours. Immunoprecipitates are electrophoresed onto Tricine gels (Invitrogen, Carlsbad, California), transferred to nitrocellulose membrane and immunoblotted with anti-CDKN1A (BD Pharmingen). Immunoblots are developed using enhanced chemiluminescence and the Super-Signal substrate according to manufacturer's instructions (Pierce Chemical Co, Rockford, Illinois).

### **Example 2** **Results Of The Analysis Of Temporal Events** **Associated With The Initial Virus-Macrophage Encounter**

#### **A. Kinetics of HIV-1 replication in adherent macrophages**

Elutriated monocytes are adhered for 7 days, exposed to an R5 HIV<sub>BaL</sub> for 90 minutes, washed and the kinetics of cellular and viral changes are monitored. HIV-1 RNA is typically detected on day 5, becoming increasingly apparent by 10-16 days after initial exposure to the virus (**Figure 1A**). In parallel, detectable p24 antigen becomes evident within 5 days, then increases dramatically (**Figure 1B**). Ultrastructurally, viral particles are not be seen in the adherent macrophages at day 1-5, although an increase in binucleated cells and then an increasing frequency of multinucleated cells can be observed (**Figure 1C**). Consistent with viral RNA and p24 antigen, virus is visibly detected by electron microscopy around day 7 (**Figure 1C; Figure 1D**) with ≥70% of the cells typically harboring large numbers of virions by day 10 (**Figure 1C; Figure 1D**). HIV-1 is being produced on the complex surfaces between cells, on the free surfaces and in cytoplasmic vacuoles

of the Golgi apparatus. Nonetheless, once the majority of cells are infected and large numbers of virions are present within and on the surface of the macrophages, p24 levels plateau, likely dependent on host factors.

#### **B. Initial Gene Expression In HIV-1-Infected Macrophage Populations**

To examine the host factors underlying viral propagation, transcriptional pathways that activated downstream of the CD4-HIV-1 co-receptor binding/signaling event are examined by cDNA expression arrays. Compared with the control mock-infected macrophage population, an early and transient gene expression profile occurs, followed by a delayed pattern that emerges in association with viral replication. Within 3-6 hours upregulated genes defined as exhibiting a  $\geq 2$  fold increase above baseline in  $\geq 4$  donors (134 of 1200 interrogated) are associated predominantly with signal transduction pathways (24%) and transcription (25%) (**Figure 2**), many consistent with downstream effects of engaging the G protein signaling pathway. Genes corresponding to the mitogen activated protein kinase (MAPK) family are increased, including p38 MAPK and MAPKAP-K2. In addition to genes involved in transcription and signal transduction, multiple genes associated with cell cycle, apoptosis, and cellular recruitment (**Table 1**), including chemokines (IL-8, MCP-1, and MRP14) involve viral replication (Lane, B.R. *et al.* (2001) "INTERLEUKIN-8 STIMULATES HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REPLICATION AND IS A POTENTIAL NEW TARGET FOR ANTIRETROVIRAL THERAPY," *J Virol* 75:8195-8202; Cinque, P. *et al.* (1998) "ELEVATED CEREBROSPINAL FLUID LEVELS OF MONOCYTE CHEMOTACTIC PROTEIN-1 CORRELATE WITH HIV-1 ENCEPHALITIS AND LOCAL VIRAL REPLICATION," *Aids* 12:1327-1332; Strasser, F. *et al.* (1997) "ELEVATED SERUM MACROPHAGE INHIBITORY FACTOR-RELATED PROTEIN (MRP) 8/14 LEVELS IN ADVANCED HIV INFECTION AND DURING DISEASE EXACERBATION," *J Acquir Immune Defic Syndr Hum Retrovirol* 16:230-238) are upregulated. Enhanced surface adhesion molecules VNRA, CD11c, ICAM1, FNRA, CD44, ITGAE can influence HIV infection, virion interaction with the target cell and syncytium

- formation (Shattock, R.J. *et al.* (1996) “ENHANCED HIV REPLICATION IN MONOCYTIC CELLS FOLLOWING ENGAGEMENT OF ADHESION MOLECULES AND CONTACT WITH STIMULATED T CELLS,” *Res Virol* 147:171-179) and also an incorporation into HIV virions (Guo, M.M. *et al.* (1995) “HIV ACQUIRES FUNCTIONAL ADHESION RECEPTORS FROM HOST CELLS,” *AIDS Res Hum Retroviruses* 11: 1007-1013).

<b>Table 1</b> <b>Early HIV-1 Upregulated Macrophage Gene Expression</b>		
<b>GenBank Accession Number</b>	<b>Gene Description</b>	<b>Average Fold Increase (&gt;4 of 8) Donors</b>
<b>Cell Cycle/Apoptosis</b>		
U13737	caspase-3	2.2
L29222	CDC-like kinase (CLK1)	2.1
AF071596	IEX-1L anti-death protein	2.1
M15796	proliferating cyclic nuclear antigen (PCNA)	2.1
X96586	FAN protein	2.1
U28014	caspase-4	2.1
Z23115	bcl-x	2.0
U09579	cyclin-dependent kinase inhibitor 1A (CDKN1A)	2.0
<b>Adhesion Molecules/Receptors</b>		
M14648	vitronectin receptor alpha (VNRA)	3.3
M81695	CD11c antigen	2.5
J03132	intercellular adhesion molecule 1 (ICAM1)	2.5
X06256	fibronectin receptor alpha (FNRA)	2.5
D84657	photolyase/blue-light receptor homolog	2.5
X07979	fibronectin receptor beta (FNRB)	2.4
D13866	alpha 1 catenin	2.4
X01060	transferrin receptor	2.3
M59911	integrin alpha 3 (ITGA3)	2.3
M37722	fibroblast growth factor receptor 1	2.2
X72304	corticotropin releasing factor receptor 1	2.2
M59040	CD44 antigen	2.1
L25851	integrin alpha E (ITGAE)	2.1
M27492	IL-7 receptor type I	2.0
J04536	leukosialin	2.0
X01057	IL2R alpha	2.0
<b>Chemokines/Cytokines</b>		
Y00787	interleukin-8	9.7
M65291	interleukin-12 alpha	5.0

**Table 1**  
**Early HIV-1 Upregulated Macrophage Gene Expression**

GenBank Accession Number	Gene Description	Average Fold Increase (>4 of 8) Donors
M24545	monocyte chemotactic protein 1 (MCP-1)	4.0
X01394	tumor necrosis factor alpha (TNF alpha)	3.4
X06233	migration inhibitory factor-related protein 14 (MRP14)	3.3
M17733	thymosin beta 4	3.1
M92381	thymosin beta10	3.0
X53655	neurotrophin-3 precursor	2.6
M21121	small inducible protein A5 (SCYA5)	2.3
M86492	glia maturation factor beta	2.2
M31145	insulin-like growth factor binding protein 1	2.2
X02530	interferon gamma-induced protein	2.1
M27288	oncostatin M (OSM)	2.1
U16296	T-lymphoma-invasion & metastasis inducing (TIAM1)	2.0
M25667	neuromodulin	2.0
<b>Proteases/ Protease Inhibitors</b>		
X07549	Cathepsin H	5.0
M11233	cathepsin D	3.0
X56692	C reactive protein	2.9
AF059244	cystatin related protein	2.8
J05070	matrix metalloproteinase 9 (MMP9)	2.8
X05562	procollagen alpha 2	2.5
M36717	ribonuclease/angiogenin inhibitor (RAI)	2.4
L23808	matrix metalloproteinase 12	2.2
D00762	proteasome C8	2.1
Z81326	protease inhibitor 1alpha	2.0
X87212	cathepsin C	2.0
L40377	cytoplasmic antiprotease 2 (CAP2)	2.0
M23254	calpain 2	2.0
<b>Metabolism</b>		
U03688	dioxin inducible cytochrome p450 (CYP1A1)	4.4
X06985	heme oxygenase 1 (HO-1)	4.2
U34683	glutathione synthetase	3.0
X07270	90-kDa heat-shock protein A	2.7
U29091	selenium binding protein	2.7
L14595	neural amino acid transporter A (SATT)	2.6
M33374	NADH dehydrogenase 1b	2.5
D00099	Na+/K+ transporting ATPase	2.4

<b>Table 1</b> <b>Early HIV-1 Upregulated Macrophage Gene Expression</b>		
<b>GenBank Accession Number</b>	<b>Gene Description</b>	<b>Average Fold Increase (&gt;4 of 8) Donors</b>
	alpha 1	
M74524	ubiquitin conjugating enzyme (UBE2A)	2.3
X91247	thioredoxin reductase	2.3
X54079	27-kDa heat-shock protein	2.1
M11717	70-kDa heat shock protein 1	2.1
L20046	xeroderma pigmentosum group G complementing protein	2.0
Y00264	Alzheimer's disease amyloid A4 protein	2.0

Although gene expression for caspases 3, 4 and 8 is increased, genes encoding factors that contribute to cellular resistance to apoptosis including IEX-1L and bcl-x (Wu, M.X. *et al.* (1998) "IEX-1L, AN APOPTOSIS INHIBITOR INVOLVED IN NF-KAPPAB-MEDIATED CELL SURVIVAL, Science 281:998-1001;

5 Antonsson, B. *et al.* (2000) "THE BCL-2 PROTEIN FAMILY," Exp Cell Res 256:50-57) are concurrently elevated (Table 1). As reported, IL-2 receptor mRNA is also enhanced in HIV-infected macrophages (Allen, J.B. *et al.* (1990) "Expression of interleukin 2 receptors by monocytes from patients with acquired

10 immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro," J Clin Invest 85:192-199). Another gene upregulated in infected cells within hours and at day 1 is CYP1A1, previously associated with enhanced HIV-1 gene expression *in vitro* and with acceleration in the progression of AIDS mediated by an oxidative stress pathway Yao, Y. *et al.* (1995) "DIOXIN ACTIVATES HIV-1 GENE EXPRESSION BY AN OXIDATIVE STRESS

15 PATHWAY REQUIRING A FUNCTIONAL CYTOCHROME P450 CYP1A1 ENZYME," Environ Health Perspect 103:366-71). However, the augmented transcriptional activity for heme oxygenase-1 (HO-1) a multifunctional protein that plays a role in the regulation of cellular heme could protect these viral host cells against oxidative stress and is increased in PBMC of AIDS patients (Levere, R.D. *et al.* (1993)

20 "ELEVATED LEVELS OF HEME OXYGENASE-1 ACTIVITY AND MRNA IN PERIPHERAL

BLOOD ADHERENT CELLS OF ACQUIRED IMMUNODEFICIENCY SYNDROME PATIENTS,” *Am J Hematol* 43, 19-23).

HO-1, together with increased glutathione synthetase (**Table 1**) may help provide a balance and protect the macrophage from oxidative stress generated by the virus (Mialocq, P. *et al.* (2001) “OXIDATIVE METABOLISM OF HIV-INFECTED MACROPHAGES: THE ROLE OF GLUTATHIONE AND A PHARMACOLOGIC APPROACH,” *Pathol Biol (Paris)* 49:567-571; Toborek, M. *et al.* (2003) “HIV-TAT PROTEIN INDUCES OXIDATIVE AND INFLAMMATORY PATHWAYS IN BRAIN ENDOTHELIUM,” *J Neurochem* 84:169-179). Furthermore, transcription for the host cell Tat binding protein (TBP-1) that interacts with viral Tat is rapidly elevated in HIV infected macrophages )Nelbock, P. *et al.* (1990) “A CDNA FOR A PROTEIN THAT INTERACTS WITH THE HUMAN IMMUNODEFICIENCY VIRUS TAT TRANSACTIVATOR,” *Science* 248:1650-1653 (1990). In the early virus-induced transcriptional events, HIV-1 clearly enhances more genes than it suppresses since only tripeptidyl peptidase I, a lysosomal serine protease with a minor endoprotease activity responsible for cleaving tripeptides from the N terminus of oligopeptides (Tomkinson, B. (1999) “Tripeptidyl peptidases: enzymes that count,” *Trends Biochem Sci* 24:355-359) is reproducibly suppressed. Since this protein is involved in protein turnover, control of its expression in the host cell could benefit the virus to ensure that infection is established.

### **C. Kinetics of HIV-1 Induced Gene Expression**

The initial pattern of expression observed following binding of HIV-1 to macrophages in 4-7 donors, consistent with receptor engagement, is transient and by 24 hr, a restricted number of genes remain or are newly elevated (**Table 2**).

<b>Table 2</b> <b>Genes Upregulated in Macrophages from Day 1-14 after HIV-1 Infection</b>		
<b>GenBank Accession Number</b>	<b>Gene Description</b>	<b>Fold Increase</b>
<b>Day 1</b>		
M17733	thymosin beta 4	4.6
X15480	glutathione S-transferase pi	3.4
X12451	cathepsin L	3.0
M24545	monocyte chemotactic protein 1 (MCP-1)	2.7
L16785	nucleoside diphosphate kinase B	2.7
X93499	ras-related protein RAB-7	2.5
U07418	mutL protein homolog1 (MLH1)	2.4
M15796	proliferating cyclic nuclear antigen (PCNA)	2.4
M83234	nuclease sensitive element (NSEP)	2.3
D10495	protein kinase C delta	2.3
Z29678	microphthalmia-assoc. transc. factor(MITF)	2.3
X04106	calpain	2.3
X02920	alpha-1-antiproteinase	2.2
M19922	INT-2 proto-oncogene protein	2.2
L41816	calcium/calmodulin-dependent protein kinase I(camki)	2.2
X79067	EGF response factor 1	2.1
U18840	myelin-oligodendrocyte glycoprotein	2.1
U03688	CYP1B1	2.1
X69391	60S ribosomal protein L6 (RPL6)	2.1
M92381	thymosin beta-10	2.1
K02770	interleukin-1 beta	2.1
X06233	calgranulin B	2.0
M97796	inhibitor of DNA binding 2 protein	2.0
M59911	integrin alpha 3 (ITGA3)	2.0
AF055581	lnk adaptor protein	2.0
X67951	thioredoxin peroxidase 2 (TDPX2)	2.0
<b>Day 3</b>		
D88378	proteasome inhibitor HPI31	8.3
D28118	ZNF 161	2.6
M26708	prothymosin alpha	2.1
J05070	matrix metalloproteinase 9 (MMP9)	2.0
M29366	ERBB-3 receptor	2.0
U09579	CDKN1A	2.0
<b>Day 5</b>		
M24545	monocyte chemotactic protein 1 (MCP-1)	2.3
M14631	guanine nucleotide-binding protein(GNAS)	2.2
X04106	calpain	2.1

<b>Table 2</b> <b>Genes Upregulated in Macrophages from Day 1-14 after HIV-1 Infection</b>		
<b>GenBank Accession Number</b>	<b>Gene Description</b>	<b>Fold Increase</b>
U07418	mutL protein homolog1 (MLH1)	2.1
<b>Day 7</b>		
Y00796	integrin alpha L (ITGAL)	8.7
X15014	Ral A; GTP-binding protein	3.5
<b>U09579</b>	<b>CDKN1A</b>	<b>3.5</b>
L16785	nucleoside diphosphate kinase B	3.1
X01057	IL-2 receptor alpha	2.9
M29870	Rac1	2.5
M23619	high mobility group protein (HMG-I)	2.3
X93499	ras related protein RAB-7	2.3
U07418	mutL protein homolog1 (MLH1)	2.2
D28118	zinc finger protein 161 (ZNF161)	2.2
L25080	Ras homolog A (RhoA)	2.1
X08020	glutathione S-transferase mu 1	2.0
<b>Day 14</b>		
<b>U09579</b>	<b>CDKN1A</b>	<b>7.9</b>
U07418	mutL protein homolog1 (MLH1)	3.8
U48296	nuclear tyrosine phosphatase (PRL1)	3.7
U12779	MAPKAP Kinase 2	3.3
D15057	defender against cell death 1(DAD1)	3.2
J04111	jun proto-oncogene	3.1
L07597	S6KII alpha 1	3.1
M23619	high mobility group protein (HMG-I)	2.8
X69391	60s ribosomal protein L6	2.5
L25080	Ras homolog A (RhoA)	2.5
U12979	PC4	2.5
X08804	ras-related protein RAP-1B	2.4
M74524	ubiquitin-conjugating enzyme E2	2.2
M17733	thymosin beta 4	2.2
U28014	caspase 4	2.2
U51004	PKC inhibitor 1	2.2
U08316	S6KII alpha 3	2.0

Of considerable interest are the limited detectable alterations in gene expression in the cells between 3-5 days after infection, preceding evidence of viral replication. Concomitant with evidence of the HIV replicative cycle (**Figure 1**), a resurgence of gene expression begins to manifest (**Table 2**, days 7-14). Albeit the



majority of cells are maximally producing HIV by day 10-16 (**Figure 1**), only a limited repertoire of genes is upregulated compared to control macrophages (**Table 2**). Among these are several G-protein related molecules, which could reflect cell-cell transmission and HIV-1 induced signaling. MutL protein homolog 1 (MLH1),  
5 a component of the DNA mismatch repair gene (Modrich, P. (1997) “STRAND-SPECIFIC MISMATCH REPAIR IN MAMMALIAN CELLS,” J Biol Chem 272:24727-30) is also increased consistently, not only within a few hours of encountering the virus (**Table 1**), but during the progression of infection (days 1, 5, 7 and 14) (**Table 2**). This protein could be playing a role in aiding to repair DNA damage after viral  
10 integration into the host and thus preserving genome stability to continue the viral life cycle. Furthermore, transcription of the anti-apoptotic gene DAD1 (Hong, N.A. *et al.* (2000) “MICE LACKING DAD1, THE DEFENDER AGAINST APOPTOTIC DEATH-1, EXPRESS ABNORMAL N-LINKED GLYCOPROTEINS AND UNDERGO INCREASED EMBRYONIC APOPTOSIS. Dev Biol 220:76-84) is enhanced at the peak  
15 of viral replication. Although the proteasome inhibitor HPI31 subunit (**Table 2**) is elevated at 3 days after infection, it is dramatically decreased during replication, consistent with evidence that proteasome activity is essential for viral maturation (Schubert, U. *et al.* (2000) “PROTEASOME INHIBITION INTERFERES WITH GAG POLYPROTEIN PROCESSING, RELEASE, AND MATURATION OF HIV-1 AND HIV-2,”  
20 Proc Natl Acad Sci USA 97:13057-13062). This may reflect a tight control of the macrophage metabolism to regulate protein turnover at this late stage of infection to preserve integrity of viral protein or host cell factors necessary for efficient virion maturation and release (Schubert, U. *et al.* (2000) “PROTEASOME INHIBITION INTERFERES WITH GAG POLYPROTEIN PROCESSING, RELEASE, AND MATURATION  
25 OF HIV-1 AND HIV-2,” Proc Natl Acad Sci USA 97:13057-13062).

#### **D. Increased CDKN1A Gene And Protein Expression In Virus Infected Macrophages**

One of the genes that exhibited a unique biphasic expression pattern is CDKN1A. Because it is rapidly upregulated following HIV-1 binding/entry and  
30 then again during the emergence of viral replication (**Figure 3A**), this gene is

selected for further study. RNase protection assay (RPA) confirmed the rapid induction of CDKN1A (**Figure 3B**; **Figure 3C**), followed by maximum expression concomitant with viral infection with no corresponding changes in another cell cycle related gene p53. To further explore the relationship between viral infection and p21, p21 protein expression is examined by immunofluorescence. Not only increased nuclear, but also cytoplasmic p21 staining is observed in infected cells (**Figure 4A**; **Figure 4B**), consistent with enhanced protein expression in whole cell lysates detected by western blot (**Figure 4C**).

To determine whether the increased p21 influenced viral life cycle, the cells are treated with two distinct p21 anti-sense oligonucleotides (**SEQ ID NO. 7** and **SEQ ID NO. 9**). Both oligonucleotides reduce viral replication as assessed by p24 levels, most evident at day 12 when untreated cells show substantial HIV-1 production. In contrast, a missense control oligonucleotide (**SEQ ID NO. 13**) did not suppress HIV-1 p24 (**Figure 4D**). The oligonucleotides have no negative effect on cell viability in infected or uninfected macrophage cultures as determined by cell number, morphology and ultrastructural analysis. Moreover, the p21 oligos have no direct effect on macrophage CD4 nor CCR5.

#### **E. Effect of CDDO on HIV-1 replication**

The ability of p21 oligonucleotides to block HIV-1 replication prompted the exploration of potential therapeutically relevant mechanisms of modulating p21 to inhibit HIV-1. It has been reported that peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) ligands, one of which includes the synthetic triterpenoid CDDO, modulate p21 activity (Wang, Y. *et al.* (2000) "A SYNTHETIC TRITERPENOID, 2-CYANO-3,12-DIOXOLEANA-1,9-DIEN-28-OIC ACID (CDDO), IS A LIGAND FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA," *Mol Endocrinol* 14:1550-1556); Wakino, S. *et al.* (2001) "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGANDS INHIBIT MITOGENIC INDUCTION OF P21(CIP1) BY MODULATING THE PROTEIN KINASE CDELTA PATHWAY IN VASCULAR SMOOTH MUSCLE CELLS," *J Biol Chem* 276, 47650-47657). To examine the effect

of this synthetic triterpenoid, CDDO (0.1  $\mu$ M) and its derivative di-CDDO are added prior to, or at the time of, infection of macrophages with HIV-1, resulting in a dose dependent suppression in the release of the viral protein p24 Ag (**Figure 5A**). Without reducing cell viability or cell number, both CDDO and di-CDDO dramatically reduced the levels of detectable virus (**Figure 5B**; **Figure 5C**). Paradoxically, neither CDDO or di-CDDO decreases p21 protein levels concomitant with reducing HIV infection (**Figure 5D**). Moreover, p21 protein accumulates in uninfected cells, suggesting a post-translational effect on the p21 pathway.

10

### **Example 3 Analysis Of Gene Silencing**

Gene silencing was carried out using SMARTpool™ si RNA duplexes (Dharmacon), which targets CDKN1A. A non-specific si RNA pool (Dharmacon) was also utilized as a negative control. After preparing siRNA:Lipofectamine 2000 complexes cells were transfected according to manufacture's instructions (Invitrogen-Life Technologies). Macrophages were infected after four days of transfection.

15

The results obtained with the antisense oligonucleotides were confirmed using gene silencing technology. Macrophages treated with CDKN1A si RNA duplexes, show a reduction in HIV-1 replication as determined by p24 ELISA on 14 days supernatants. This is not the case if macrophages are treated with a non-specific si RNA duplexes control.

20

### **Example 4 Analysis Of Temporal Events Associated With The Initial Virus-Macrophage Encounter**

25

The present invention demonstrates that HIV-1 infection promotes successful viral replication by modulating macrophage gene transcription. In comparison to previous studies, using viral envelope gp120 (Popik, W. *et al.* (2000) "EXPLOITATION OF CELLULAR SIGNALING BY HIV-1: UNWELCOME GUESTS WITH MASTER KEYS THAT SIGNAL THEIR ENTRY," *Virology* 276:1-6; Cicala, C. *et*

30

*al.* (2002) “HIV ENVELOPE INDUCES A CASCADE OF CELL SIGNALS IN NON-PROLIFERATING TARGET CELLS THAT FAVOR VIRUS REPLICATION,” *Proc. Natl. Acad. Sci. USA* 99:9380-9385; Liu, Q.H. *et al.* (2000) “HIV-1 GP120 AND CHEMOKINES ACTIVATE ION CHANNELS IN PRIMARY MACROPHAGES THROUGH CCR5 AND CXCR4 STIMULATION,” *Proc. Natl. Acad. Sci. USA* 97:4832-4837), one aspect of the invention relates to the finding that intact, infectious R5 HIV-1 induces a cascade of events associated with reproducible alteration of gene transcription in primary macrophage hosts. Consistent with viral binding to CD4 and CCR5 seven transmembrane G protein receptors, viral initiated signal transduction induces transcriptional changes. While the functional significance attributable to each of the 134 genes upregulated within hours after viral binding is complex, the data support an initial burst of transcriptional activity followed by a quiescent phase and a resurgence of new genes associated with viral replication. In addition to phosphorylation of p38 MAPK, HIV-1 enhanced gene expression of p38 MAPK and downstream mediators, such as, MAPKAP-2, which may be critical in early post-entry and late stages of HIV-1 infection (Del Corno, M. *et al.* (2001) “HIV-1 GP120 AND CHEMOKINE ACTIVATION OF PYK2 AND MITOGEN-ACTIVATED PROTEIN KINASES IN PRIMARY MACROPHAGES MEDIATED BY CALCIUM-DEPENDENT, PERTUSSIS TOXIN-INSENSITIVE CHEMOKINE RECEPTOR SIGNALING,” *Blood* 98:2909-2916; Shapiro, L. *et al.* (1998) “ROLE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN HIV TYPE 1 PRODUCTION IN VITRO,” *Proc. Natl. Acad. Sci. USA* 95:7422-7426 (1998), and p38 MAPK also plays an important role in multiple aspects of the immune response (Dong, C. *et al.* (2002) “MAP KINASES IN THE IMMUNE RESPONSE,” *Ann. Rev. Immunol* 20, 55-72 (2002). MAPK also contributes to chemokine expression and recruitment of leukocytes, and inhibition of p38 MAPK reportedly also abrogates gp120-induced MMP9 in T cells (Misse, D. *et al.* (2001) “HIV-1 GLYCOPROTEIN 120 INDUCES THE MMP-9 CYTOPATHOGENIC FACTOR PRODUCTION THAT IS ABOLISHED BY INHIBITION OF THE P38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY,” *Blood* 98:541-547). MMP9, a member of the matrix metalloproteinase gene family is one of the genes expressed at day 3 after viral infection of macrophages that can

facilitate the migration of HIV-infected monocytes across the vascular endothelium (Dhawan, S. *et al.* (1995) "HIV-1 INFECTION ALTERS MONOCYTE INTERACTIONS WITH HUMAN MICROVASCULAR ENDOTHELIAL CELLS," J Immunol 154:422-432 (1995) and has been detected in the cerebrospinal fluids of HIV-1 patients (Sporer, B. *et al.* (1998) "PRESENCE OF MATRIX METALLOPROTEINASE-9 ACTIVITY IN THE CEREBROSPINAL FLUID OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS," J. Infect. Dis. 178:854-857). Recruitment of viral host cells may also occur in response to increased MCP-1 expression consistent with the results obtained by other investigators (Mengozi, M. *et al.* (1999) "HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INDUCES MONOCYTE CHEMOTACTIC PROTEIN-1 IN HUMAN MACROPHAGES AND U937 PROMONOCYTIC CELLS," Blood 93:1851-1857). Enhanced gene transcription for other inflammatory mediators associated with increased viral replication in macrophages and pathophysiology of HIV, including TNF $\alpha$ , IP-10, MRP14, IL-8 and LIF (Lane, B.R. *et al.* (2001) "INTERLEUKIN-8 STIMULATES HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REPLICATION AND IS A POTENTIAL NEW TARGET FOR ANTIRETROVIRAL THERAPY," J Virol 75:8195-202; Strasser, F. *et al.* (1997) "ELEVATED SERUM MACROPHAGE INHIBITORY FACTOR-RELATED PROTEIN (MRP) 8/14 LEVELS IN ADVANCED HIV INFECTION AND DURING DISEASE EXACERBATION," J Acquir Immune Defic Syndr Hum Retrovirol 16:230-238); Kinter, A. *et al.* (2000) "CHEMOKINES, CYTOKINES AND HIV: A COMPLEX NETWORK OF INTERACTIONS THAT INFLUENCE HIV PATHOGENESIS," Immunol Rev 177:88-98; Agostini, C. *et al.* (2000) "CXC CHEMOKINES IP-10 AND MIG EXPRESSION AND DIRECT MIGRATION OF PULMONARY CD8+/CXCR3+ T CELLS IN THE LUNGS OF PATIENTS WITH HIV INFECTION AND T-CELL ALVEOLITIS," Am J Respir Crit Care Med 162:1466-1473; Broor, S. *et al.* (1994) "STIMULATION OF HIV REPLICATION IN MONONUCLEAR PHAGOCYTES BY LEUKEMIA INHIBITORY FACTOR," J Acquir Immune Defic Syndr 7:647-654) were also reproducibly detected. Cell homeostasis and genomic stability may be aided by glutathione synthetase, heme oxygenase-1 and MLH1 ensuring the survival of the macrophage to allow viral replication. Furthermore, reduction of lysosomal enzyme activity can potentially enhance virus entry and infectivity in the host cell

(Fredericksen, B.L. *et al.* (2002) “INHIBITION OF ENDOSOMAL/LYSOSOMAL DEGRADATION INCREASES THE INFECTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS,” *J Virol* 76, 11440-11446).

Macrophages can co-exist with the virus for a prolonged time, during  
5 which they contribute to the pathogenesis of AIDS, acting as viral reservoirs and  
transmitting HIV-1 to neighboring cells. Although proapoptotic genes for caspase  
3, 4 and 8 were upregulated within 3 hours after infection, the antiapoptotic genes  
bcl-x, DAD1 and IEX-1L (Wu, M.X. *et al.* (1998) “IEX-1L, AN APOPTOSIS  
INHIBITOR INVOLVED IN NF-KAPPA-B-MEDIATED CELL SURVIVAL,” *Science* 281:998-  
10 1001; Antónsson, B. *et al.* (2000) “THE BCL-2 PROTEIN FAMILY,” *Exp Cell Res*  
256:50-57; Hong, N.A. *et al.* (2000) “MICE LACKING DAD1, THE DEFENDER  
AGAINST APOPTOTIC DEATH-1, EXPRESS ABNORMAL N-LINKED GLYCOPROTEINS AND  
UNDERGO INCREASED EMBRYONIC APOPTOSIS,” *Dev Biol* 220:76-84), were also  
increased by HIV-1. The balance between pro and anti-apoptotic genes must favor  
15 the survival of virus-infected macrophages *in vitro* and *in vivo*, as a strategy  
developed by the virus to prolong the life of the host for its uninterrupted cycle of  
replication.

As indicated above, following the initial HIV-1 induced burst of gene  
expression (6-24 hr), little evidence of transcriptional activity occurred until the  
20 onset of viral replication, when an increase in host molecules was again detected  
(day 7-14). The lack of induction of new host molecules during this interim period  
may allow the infected cells to escape immune surveillance while the virus initiates  
its life cycle to commence replication. Once ready to replicate, new transcription  
may be essential to facilitate the replicative process. For example the data indicate  
25 CDKN1A/p21 as a host molecule critical to viral replication in macrophages.  
CDKN1A is a cyclin-dependent kinase inhibitor induced during G1 cell cycle,  
arrest by p53-dependent pathway following DNA damage, as well as p53-  
independent pathways involving growth factors

Dotto, G.P. (2000) “p21(WAF1/CIP1): MORE THAN A BREAK TO THE CELL CYCLE?,” *Biochim Biophys Acta* 1471:M43-56; Ogryzko, V.V. *et al.* (1997) “WAF1 RETARDS S-PHASE PROGRESSION PRIMARILY BY INHIBITION OF CYCLIN-DEPENDENT KINASES,” *Mol Cell Biol* 17, 4877-4882 (1997); Zeng, Y.X. *et al.* (1996) “REGULATION OF P21 WAF1/CIP1 EXPRESSION BY P53-INDEPENDENT PATHWAYS,” *Oncogene* 12:1557-1564). Progressive upregulation of p21 mRNA and protein have also been associated with maturation of hematopoietic progenitor cells (Steinman, R.A. *et al.* (1998) “REGULATION OF P21(WAF1) EXPRESSION DURING NORMAL MYELOID DIFFERENTIATION,” *Blood* 91:4531-4542), but its connection with viral replication in macrophages has not been demonstrated. Increased p21 in skin lesions of human papillomavirus has been found to be further enhanced by HIV co-infection (Arany, I. *et al.* (1997) “p53, WAF1/CIP1 AND MDM2 EXPRESSION IN SKIN LESIONS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS AND HUMAN IMMUNODEFICIENCY VIRUS,” *Anticancer Res* 17:1281-1285). An upregulation in CDKN1A induced in macrophages infected with the opportunistic bacteria, *Mycobacterium avium* (Greenwell-Wild, T. *et al.* (2002) “MYCOBACTERIUM AVIUM INFECTION AND MODULATION OF HUMAN MACROPHAGE GENE EXPRESSION,” *J Immunol* 169:6286-6297 (2002) may also be linked to the increased susceptibility for HIV replication reported in these cells (Wahl, S.M. *et al.* (1998) “MYCOBACTERIUM AVIUM COMPLEX AUGMENTS MACROPHAGE HIV-1 PRODUCTION AND INCREASES CCR5 EXPRESSION,” *Proc Natl Acad Sci USA* 95:12574-12579). The specific role played by CDKN1A in HIV-1 macrophage infection has not been fully determined, however, it may either directly or indirectly enhance viral replication. Although originally described as a cell cycle inhibitor, CDKN1A has more recently been associated with apoptosis, cytoplasmic regulation of nuclear import, and transcriptional regulation by its capacity to act as a transcriptional co-factor/adaptor molecule (Coqueret, O. (2003) “NEW ROLES FOR P21 AND P27 CELL-CYCLE INHIBITORS: A FUNCTION FOR EACH CELL COMPARTMENT?,” *Trends Cell Biol* 13:65-70; LaBaer, J. *et al.* (1997) “NEW FUNCTIONAL ACTIVITIES FOR THE P21 FAMILY OF CDK INHIBITORS,” *Genes Dev* 11:847-862). In this regard, HIV-1 Tat is essential for efficient viral replication

and interacts with cAMP response element binding protein (CREB) and the transcriptional coactivator p300 (Hottiger, M.O. *et al.* (1998) "INTERACTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TAT WITH THE TRANSCRIPTIONAL COACTIVATORS P300 AND CREB BINDING PROTEIN," J Virol 72:8252-8256), which  
5 can be stimulated by the coexpression of CDKN1A through a novel transcriptional repression domain on p300 (Snowden, A.W. *et al.* (2000) "A NOVEL TRANSCRIPTIONAL REPRESSION DOMAIN MEDIATES P21(WAF1/CIP1) INDUCTION OF P300 TRANSACTIVATION," Mol Cell Biol 20, 2676-2686). In addition, an increase in TBP-1 could be a strategy of the virus to ensure efficient regulation of viral  
10 transcription and replication. A causal relationship is thus established between HIV and induced p21 expression, which appears to support viral replication in macrophages.

While the initial enhancement of p21 gene expression likely represents a downstream consequence of CCR5/G protein signaling, the rise in gene  
15 transcription could be due to either intracellular or extracellular viral signals. Definition of such factors may provide a means of altering host involvement in viral infection and replication kinetics, possibly in conjunction with antiviral therapy. The presence of p21 in the nucleus has been related to its cell cycle functions (Dotto, G.P. (2000) "P21(WAF1/CIP1): MORE THAN A BREAK TO THE  
20 CELL CYCLE?" Biochim Biophys Acta 1471:M43-56) and the cytoplasmic localization of this protein has been implicated in controlling/preventing apoptosis of alveolar macrophages and during monocytic differentiation (Tomita, K. *et al.* (2002) "INCREASED P21(CIP1/WAF1) AND B CELL LYMPHOMA LEUKEMIA-X(L) EXPRESSION AND REDUCED APOPTOSIS IN ALVEOLAR MACROPHAGES FROM  
25 SMOKERS," Am J Respir Crit Care Med 166:724-731; Asada, M. *et al.* (1999) "APOPTOSIS INHIBITORY ACTIVITY OF CYTOPLASMIC P21(CIP1/WAF1) IN MONOCYTIC DIFFERENTIATION," Embo J 18:1223-1234). Increased p21 protein in both nuclear and cytoplasmic compartments of HIV-1 infected macrophages may both generate a permissive environment for viral replication and prevent the death  
30 of the host cells. The ability to dramatically suppress HIV-1 replication with the



p21 anti-sense oligonucleotides indicates that CDKN1A is critical in promoting viral replication. CDDO a synthetic oleanane triterpenoid with potent differentiating, anti-proliferative and anti-inflammatory activities (Suh, N. *et al.* (1999) "A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity," *Cancer Res* 59:336-341) being developed as a chemotherapeutic agent for cancer Stadheim, T.A. *et al.* (2002) "THE NOVEL TRITERPENOID 2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OIC ACID (CDDO) POTENTLY ENHANCES APOPTOSIS INDUCED BY TUMOR NECROSIS FACTOR IN HUMAN LEUKEMIA CELLS," *J Biol Chem* 277:16448-16455 (2002) may also inhibit HIV-1 via a p21-dependent pathway, possibly by a post-translational mechanism. CDDO has been recently identified as a member of a new class of nuclear PPAR $\gamma$  ligands (Wang, Y. *et al.* (2000) "A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma," *Mol Endocrinol* 14:1550-1556), which reportedly reduces p21 protein expression (Wakino, S. *et al.* (2001) "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGANDS INHIBIT MITOGENIC INDUCTION OF P21(CIP1) BY MODULATING THE PROTEIN KINASE C $\delta$  PATHWAY IN VASCULAR SMOOTH MUSCLE CELLS," *J Biol Chem* 276:47650-47657). PPAR $\gamma$  is a nuclear hormone receptor implicated in the gene regulation of lipid and glucose metabolism, cellular differentiation and control of macrophage inflammatory responses (Bar-Tana, J. (2001) "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARGAMMA) ACTIVATION AND ITS CONSEQUENCES IN HUMANS," *Toxicol Lett* 120:9-19; Delerive, P. (2001) "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN INFLAMMATION CONTROL," *J Endocrinol* 169:453-459). Natural and synthetic agonists of PPAR $\gamma$  have been recently shown to inhibit retroviral replication (Hayes, M.M. *et al.* (2002) "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISTS INHIBIT HIV-1 REPLICATION IN MACROPHAGES BY TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL EFFECTS," *J Biol Chem* 277:16913-16919) and although the target was not defined, some studies have implicated TNF- $\alpha$  in the PPAR $\gamma$ -induced suppression of HIV (Skolnik, P.R. *et al.* (2002)

“STIMULATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS ALPHA AND GAMMA BLOCKS HIV-1 REPLICATION AND TNF $\alpha$  PRODUCTION IN ACUTELY INFECTED PRIMARY BLOOD CELLS, CHRONICALLY INFECTED U1 CELLS, AND ALVEOLAR MACROPHAGES FROM HIV-INFECTED SUBJECTS,” *J Acquir Immune Defic Syndr* 31:1-10). Still unresolved is whether the antiviral effect of CDDO is mediated through this receptor entirely by its effect on p21 function by post-translational modification (Scott, M.T. *et al.* (2000) “REVERSIBLE PHOSPHORYLATION AT THE C-TERMINAL REGULATORY DOMAIN OF P21(WAF1/CIP1) MODULATES PROLIFERATING CELL NUCLEAR ANTIGEN BINDING,” *J Biol Chem* 275:11529-11537), through inhibition of NF $\kappa$ B (Straus, D.S. *et al.* (2000) “15-DEOXY-DELTA 12,14-PROSTAGLANDIN J2 INHIBITS MULTIPLE STEPS IN THE NF-KAPPA B SIGNALING PATHWAY,” *Proc Natl Acad Sci USA* 97:4844-4849, modulation of p38 MAPK (Kim, J.Y. *et al.* (2002) “INVOLVEMENT OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN THE CELL GROWTH INHIBITION BY SODIUM ARSENITE,” *J Cell Physiol* 190:29-37 (2002) and/or the production of cytokines that regulate cellular and viral components, such as TGF- $\beta$  (Li, C.Y. *et al.* (1995) “POTENTIAL ROLE OF WAF1/CIP1/P21 AS A MEDIATOR OF TGF-BETA CYTOINHIBITORY EFFECT,” *J Biol Chem* 270:4971-4974; Wahl, S.M. *et al.* (1991) “MACROPHAGE- AND ASTROCYTE-DERIVED TRANSFORMING GROWTH FACTOR BETA AS A MEDIATOR OF CENTRAL NERVOUS SYSTEM DYSFUNCTION IN ACQUIRED IMMUNE DEFICIENCY SYNDROME,” *J Exp Med* 173:981-991). Comparison of genes upregulated by HIV in T lymphocytes (Corbeil, J. *et al.* (2001) “TEMPORAL GENE REGULATION DURING HIV-1 INFECTION OF HUMAN CD4+ T CELLS,” *Genome Res* 11:1198-1204) with those identified in macrophage host also revealed an early increase in genes associated with cellular defense. However, increased expression of proapoptotic transcripts, and inhibition of mitochondria and DNA repair genes is also observed, which could explain the unavoidable death pathway in HIV-1 infected T cells and survival of macrophage host. The differential gene expression and cell specific modulation of host protein function as a result of HIV-1 infection in these cell populations may help better understand the reasons leading to HIV-induced apoptosis in T cells (Corbeil, J. *et al.* (2001) “TEMPORAL GENE

REGULATION DURING HIV-1 INFECTION OF HUMAN CD4+ T CELLS,” *Genome Res* 11:1198-1204; Clark, E. *et al.* (2000) “LOSS OF G(1)/S CHECKPOINT IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CELLS IS ASSOCIATED WITH A LACK OF CYCLIN-DEPENDENT KINASE INHIBITOR P21/WAF1. *J Virol* 74, 5040-5052), while  
5 allowing the macrophage to sustain a prolonged viral burden.

Since the macrophage represents a key target for HIV-1 infection and one of the major obstacles in eradicating the virus even during HAART (Igarashi, T. *et al.* (2001) “MACROPHAGE ARE THE PRINCIPAL RESERVOIR AND SUSTAIN HIGH VIRUS LOADS IN RHESUS MACAQUES AFTER THE DEPLETION OF CD4+ T CELLS BY A HIGHLY  
10 PATHOGENIC SIMIAN IMMUNODEFICIENCY VIRUS/HIV TYPE 1 CHIMERA (SHIV): IMPLICATIONS FOR HIV-1 INFECTIONS OF HUMANS,” *Proc Natl Acad Sci USA* 98:658-663; Garbuglia, A.R. *et al.* (2001) “DYNAMICS OF VIRAL LOAD IN PLASMA AND HIV DNA IN LYMPHOCYTES DURING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): HIGH VIRAL BURDEN IN MACROPHAGES AFTER 1 YEAR OF  
15 TREATMENT,” *J Chemother* 13:188-194, the above-described data analyzing the influence of HIV on the macrophage transcriptome reveals important insights into the pattern of host cell gene expression underlying viral success in this population. CDKN1A and other virus-regulated macrophage genes critical for HIV-1 replication provide mechanisms by which to target the macrophage reservoir  
20 and/or serve as prognostic markers of disease progression.

Finally, since anti-HIV therapy is limited by the side effects that have accompanied conventional anti-retroviral drugs, and the constant emergence of drug-resistant HIV strains, CDDO provides an important candidate drug to target HIV-1, particularly in conjunction with additional anti-viral therapy, to prevent or  
25 attenuate the infection of new viral hosts.

All publications and patent documents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent document was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention  
5 and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.

SEQUENCE LISTING

	<110>	NIDCR, National Institutes of Health Wahl, Sharon Greenwell-Wild, Theresa Vazquez-Maldonado, Nancy	
5			
	<120>	Methods and Compositions for the Inhibition of HIV-1 Replication	
	<130>	03514.160	
	<160>	14	
10	<120>	Methods and Compositions for the Inhibition of HIV-1 Replication	
	<130>	03514.160	
	<160>	14	
	<170>	PatentIn version 3.2	
15	<210>	1	
	<211>	15	
	<212>	DNA	
	<213>	Homo sapiens	
20	<400>	1 uccgcgccca gcucc	15
	<210>	2	
	<211>	15	
	<212>	DNA	
	<213>	Homo sapiens	
25	<400>	2 uccgcccgcga gcucc	15
	<210>	3	
	<211>	2265	
	<212>	DNA	
30	<213>	Homo sapiens	
	<400>	3	
		gctgccgaag tcagttcctt gtggagccgg agctggggcg ggattcgccg aggcaccgag 60	
		gcactcagag gaggtgagag agcggcggca gacaacaggg gaccccgggc cgccgcccca 120	
		gagccgagcc aagcgtgccc gcgtgtgtcc ctgcgtgtcc gcgaggatgc gtgttcgcgg 180	
35		gtgtgtgctg cgttcacagg tgtttctgcg gcaggcgcca tgtcagaacc ggctggggat 240	
		gtccgtcaga acccatgcgg cagcaaggcc tgccgccgcc tcttcggccc agtggacagc 300	
		gagcagctga gccgcgactg tgatgcgcta atggcgggct gcatccagga ggcccgtgag 360	
		cgatggaact tcgactttgt caccgagaca ccactggagg gtgacttcgc ctgggagcgt 420	
		gtgcggggcc ttggcctgcc caagctctac cttcccacgg ggcccggcg aggccgggat 480	
40		gagttgggag gaggcaggcg gcctggcacc tcacctgctc tgctgcaggg gacagcagag 540	

5	gaagaccatg	tggacctgtc	actgtcttgt	acccttgtgc	ctcgctcagg	ggagcaggct	600
	gaaggggtccc	cagggtggacc	tggagactct	caggggtcgaa	aacggcggca	gaccagcatg	660
	acagatttct	accactccaa	acgccggctg	atcttctcca	agaggaagcc	ctaataccgcc	720
	cacaggaagc	ctgcagtctt	ggaagcgcg	gggcctcaaa	ggcccgtctt	acatcttctg	780
	ccttagtctc	agtttgtgtg	tcttaattat	tatttgtgtt	ttaatttaaa	cacctcctca	840
10	tgtacatacc	ctggccgccc	cctgcccccc	agcctctggc	attagaatta	tttaaacaaa	900
	aactaggcgg	ttgaatgaga	ggttcctaag	agtgtctggc	atttttattt	tatgaaatac	960
	tatttaaaagc	ctcctcatcc	cgtgttctcc	ttttcctctc	tcccggagggt	tgggtggggc	1020
	ggcttcatgc	cagctacttc	ctcctcccca	cttgtccgct	gggtggtacc	ctctggaggg	1080
	gtgtggctcc	ttcccatcgc	tgtcacaggc	ggttatgaaa	ttcaccccct	ttcctggaca	1140
15	ctcagacctg	aattcttttt	catttgagaa	gtaaacagat	ggcactttga	aggggcctca	1200
	ccgagtgggg	gcatcatcaa	aaactttgga	gtccctcac	ctcctctaag	gttgggcagg	1260
	gtgaccctga	agtgagcaca	gcctagggct	gagctgggga	cctggtaccc	tcctggctct	1320
	tgataccccc	ctctgtcttg	tgaaggcagg	gggaagggtg	ggctcctggag	cagaccaccc	1380
	cgctgcctt	catggccctt	ctgacctgca	ctggggagcc	cgtctcagtg	ttgagccttt	1440
20	tccctctttg	gtcccccgt	accttttgag	gagccccagc	taccttctt	ctccagctgg	1500
	gctctgcaat	tccctctgc	tgtgtccct	cccccttgc	ctttcccttc	agtaccctct	1560
	cagctccagg	tggctctgag	gtgctgttcc	cacccccacc	cccagctcaa	tggactggaa	1620
	gggggaaggga	cacacaagaa	gaagggcacc	ctagtcttac	ctcaggcagc	tcaagcagcg	1680
	accgccccct	cctctagctg	tgggggtgag	gggtccatgt	gggtgcacag	gcccccttga	1740
25	gtgggggttat	ctctgtgtta	gggggtatat	atgggggagt	agatctttct	aggagggaga	1800
	cactggcccc	tcaaatcgtc	cagcgacctt	cctcatccac	cccatccctc	ccagttcat	1860
	tgcactttga	ttagcagcgg	aacaaggagt	cagacatttt	aagatggtgg	cagtagaggc	1920
	tatggacagg	gcatgcccag	tgggctcata	tggggctggg	agttagttgtc	tttctggca	1980
	ctaactgtga	gccccctggag	gcactgaagt	gcttagtgta	cttggagtat	tgggggtctga	2040
30	ccccaaacac	cttccagctc	ctgtaacata	ctggcctgga	ctgttttctc	tcggctcccc	2100
	atgtgtcctg	gttcccgttt	ctccacctag	actgtaaaac	tctcgagggc	agggaccaca	2160
	ccctgtactg	ttctgtgtct	ttcacagctc	ctcccaaat	gctgaatata	cagcagggtgc	2220
	tcaataaatg	attcttagtg	actttaaaaa	aaaaaaaaaa	aaaaa		2265
	<210>	4					
	<211>	2265					
	<212>	DNA					
35	<213>	Homo sapiens					
	<400>	4					
40	tttttttttt	tttttttttt	aaagtcacta	agaatcatth	attgagcacc	tgctgtatat	60
	tcagcattgt	gggaggagct	gtgaaagaca	cagaacagta	caggggtgtg	tcctgtccct	120
	cgagagggtt	acagtctagg	tggagaaacg	ggaaccagga	cacatgggga	gccgagagaa	180
	aacagtccag	gccagtatgt	tacaggagct	ggaagggtgt	tggggtcaga	ccccaaact	240
	ccaagtacac	taagcacttc	agtgcctcca	ggggctcaac	gttagtgcca	ggaagacaaa	300
45	ctactcccag	ccccatatga	gcccacgtgg	catgccctgt	ccatagcctc	tactgccacc	360
	atcttaaaat	gtctgactcc	ttgttccgct	gctaatacaa	gtgcaatgaa	ctggggaggg	420
	atgggggtgga	tgagggaagg	cgctggacga	tttgaggggc	cagtgtctcc	ctcctagaaa	480
	gatctactcc	cccatcatat	acccctaaca	cagagataac	ccactcaag	ggggcctgtg	540
	ccaccacatg	ggaccctcac	ccccacagct	agaggagggg	gcggctcgctg	cttgagctgc	600
50	ctgaggtaga	actagggtgc	ccttcttctt	gtgtgtccct	tccccttcca	gtccattgag	660
	ctgggggtgg	gggtgggaca	ggcacctcag	agccacctgg	agctgagagg	gtactgaagg	720
	gaaaggacaa	gggggaggga	cagcagcaga	ggggaattgc	agagcccagc	tggagaagaa	780
	gggtagctgg	ggctcctcaa	aaggtacagg	ggagccaaag	agggaaaagg	ctcaacactg	840
	agacgggctc	cccagtgcag	gtcagagggg	ccatgagggc	agggcgggtg	gtctgtcca	900
	ggacccccacc	ttccccctgc	cttcacaaga	cagagggggg	tatcaagagc	caggagggtg	960

5	ccaggtcccc	agctcagccc	taggetgtgc	tcacttcagg	gtcacccctgc	ccaaccttag	1020	✓
	aggaggtgag	gggactccaa	agtttttgat	gatgccccca	ctcgggtgagg	ccccttcaaa	1080	
	gtgccatctg	tttactttct	aaatgaaaaa	gaattcaggt	ctgagtggtcc	aggaaagggg	1140	
	gtgaatttca	taaccgcctg	tgacagcgat	gggaaggagc	cacacccctc	cagagggtac	1200	
	caccacgcg	acaagtgggg	aggaggaagt	agctggcatg	aagccggccc	acccaacctc	1260	
10	cgggagagag	gaaaaggaga	acacgggatg	aggaggcttt	aaatagtatt	tcataaaata	1320	
	aaaatgccca	gcactcttag	gaacctctca	ttcaaccgcc	tagtttttgt	ttaaataatt	1380	
	ctaattgccag	aggctggggg	gcagggggcg	gccagggtat	gtacatgagg	agggtgttaa	1440	
	attaaaacac	aaataataat	taagacacac	aaactgagac	taaggcagaa	gatgtagagc	1500	
	gggcctttga	ggccctcgcg	cttcaggac	tgcaggcttc	ctgtgggagg	attagggtt	1560	
15	cctcttgag	aagatcagcc	ggcgtttgga	gtggtagaaa	tctgtcatgc	tggctcgccg	1620	
	ccgttttcga	ccctgagagt	ctccaggtec	acctggggac	ccttcagcct	gtccccctga	1680	
	gcgaggcaca	agggtacaag	acagtgcag	gtccacatgg	tcttcctctg	ctgtccccctg	1740	
	cagcagagca	ggtgaggtgc	caggccgcct	gcctcctccc	aactcatccc	ggcctcgccg	1800	
	gggccccgtg	ggaaggtaga	gcttgggcag	gccaaggccc	cgcacacgct	cccaggcgaa	1860	
20	gtcacccctcc	agtgggtgtct	cggtgacaaa	gtcgaagtcc	catcgctcac	gggcctcctg	1920	
	gatgcagccc	gccattagcg	catcacagtc	gcggctcagc	tgtctcgtgt	ccactggggc	1980	
	gaagaggcgg	cggcaggcct	tgtgtccgca	tgggttctga	cggacatccc	cagccgggtc	2040	
	tgacatggcg	cctgccgcag	aaacacctgt	gaacgcagca	cacaccgcg	aacacgcata	2100	
	ctcgcggaca	cgcagggaca	cacgcgggca	cgcttggtct	ggctctgggc	cgcggggccc	2160	
25	gggtccctctg	ttgtctgcgg	ccgctctctc	acctcctctg	agtgccctcg	tgccctcgccg	2220	
	aatccgcgcc	cagctccggc	tccacaagga	actgacttcg	gcagc		2265	
	<210>	5						
	<211>	1909						
	<212>	DNA						
	<213>	Mus musculus						
30	<400>	5						
	gagccgagag	gtgtgagccg	ccgcgggtgc	agagtctagg	ggaattggag	tcaggcgag	60	
	atccacagcg	atatccagag	attcagagcc	acaggcacca	tgtccaatcc	tggtagatgc	120	
	cgacctgttc	cgacacaggag	caaagtgtgc	cgttgtctct	tcgggtcccgt	ggacagtgag	180	
	cagttgcgcc	gtgattgcga	tgcgtctatg	gcgggtctgc	tccaggaggc	ccgagaacgg	240	
35	tggaaactttg	acttcgtcac	ggagacgcgg	ctggagggca	acttcgtctg	ggagcgcggt	300	
	cggagccctag	ggctgcccaa	ggtctacctg	agccctgggt	cccgcagccg	tgacgacctg	360	
	ggagggggaca	agaggcccg	tacttctctt	gccctgtctg	agggggccagc	tccggaggac	420	
	cacgtggcct	tgtcgtctgc	ttgcactctg	gtgtctgagc	ggcctgaaga	ttccccgggt	480	
	gggcccggaa	catctcaggg	ccgaaaacgg	aggcagacca	gcctgacaga	tttctatcac	540	
40	tccaagcgca	gattgggtctt	ctgcaagaga	aaacctgaa	gtgcccacgg	gagccccgcc	600	
	ctcttctgct	gtgggtcagg	aggcctcttc	cccatctctg	gccttagccc	tcactctgtg	660	
	tgtcttaatt	attattttgt	ttttaattta	aacgtctcct	gtatatacgc	tgccctgcct	720	
	ctcccagctc	ccaaacttaa	agttatttaa	aaaaagaaca	aaacaaaaca	aaaaaaaacc	780	
	aaaacaaaac	aaacctaaat	tagtaggagc	gtaggggcct	tagtgtgggg	gattttctatt	840	
45	atgtagatta	ttattattta	agccccctcc	aacccaagct	ctgtgtttcc	tataccggag	900	
	gaacagtcct	actgatata	acccatctgc	atccgtttca	cccaaccccc	ctccccccat	960	
	tccctgcctg	gttcccttgc	acttcttacc	tgggggtgat	cctcagacct	gaatagcact	1020	
	ttggaaaaat	gagtaggact	ttgggggtct	cttgtcacct	ctaaggccag	ctaggatgac	1080	
	agtgaagcag	tcacagccta	gaacagggat	ggcagttagg	actcaaccgt	aatatccgca	1140	
50	ctcttgacat	tgtcagacc	tgtgaagaca	ggaatgggtc	ccactctgga	tcccccttgc	1200	
	cactcctggg	gagcccacct	ctcctgtggg	tctctgccag	ctgcccctct	attttggagg	1260	
	gttaatctgg	tgatctgctg	ctcttttccc	ccaccccata	cttccccttc	tgaggtcgg	1320	
	caggaggcat	atctaggcac	ttgccccaca	gtcagtgga	ctggaaggga	atgtatatgc	1380	

—

$\langle 210 \rangle$	7
$\langle 211 \rangle$	20



<212> DNA  
<213> Mus musculus

5 <400> 7  
tgtcaggctg gtctgcctcc 20

10 <210> 8  
<211> 20  
<212> DNA  
<213> Homo sapiens

15 <400> 8  
tgtcattgctg gtctgccgcc 20

20 <210> 9  
<211> 20  
<212> DNA  
<213> Mus musculus

25 <400> 9  
acatcaccag gattggacat 20

30 <210> 10  
<211> 23  
<212> DNA  
<213> Homo sapiens

35 <400> 10  
acatccccag ccggttctga cat 23

40 <210> 11  
<211> 202  
<212> DNA  
<213> Homo sapiens

45 <400> 11.  
accatccccct tctcacctg aaaacaggca gcccaaggac aaaatagcca ccagcctctt 60  
ctatgccaga gctcaacatg ttgggacatg ttcctgacgg ccagaaagcc aatcagagcc 120  
acagcctgct gcccaagcat gttcctggga agcaggcagc atagggatgg agggaggtc 180  
agcctggggg aacaagagtg cc 202

50 <210> 12  
<211> 202  
<212> DNA  
<213> Homo sapiens

5 <400> 12  
 ggcactcttg ttccccagg ctgagcctcc ctccatccct atgctgcttg cttcccagga 60  
 acatgcttgg gcagcaggct gtggctctga ttggtttct ggccgtcagg aacatgtccc 120  
 aacatgttga gctctggcat agaagaggct ggtggctatt ttgtccttgg gctgctgtt 180  
 ttcaggtgag gaaggggatg gt 202

10 <210> 13  
 <211> 160  
 <212> PRT  
 <213> 'Homo sapiens

15 <400> 13  
 Met Ser Glu Pro Ala Gly Asp Val Arg Gln Asn Pro Cys Gly Ser Lys  
 1 5 10 15  
 Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser Arg  
 20 25 30  
 Asp Cys Asp Ala Leu Met Ala Gly Cys Ile Gln Glu Ala Arg Glu Arg  
 35 40 45  
 Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly Asp Phe Ala  
 50 55 60  
 Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys Leu Tyr Leu Pro Thr  
 65 70 75 80  
 Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly Gly Arg Arg Pro Gly  
 85 90 95  
 Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala Glu Glu Asp His Val Asp  
 100 105 110  
 Leu Ser Leu Ser Cys Thr Leu Val Pro Arg Ser Gly Glu Gln Ala Glu  
 115 120 125  
 Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln  
 130 135 140  
 Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser  
 145 150 155 160

45 <210> 14  
 <211> 18  
 <212> DNA  
 <213> Mus musculus

50 <400> 14  
 tggatccgac atgtcaga 18

**What Is Claimed Is:**

- 5  
10  
15  
20
- Claim 1. A method of attenuating the transmission or infection of an immunodeficiency virus into a cell comprising providing to said cell an inhibitor of p21, wherein said inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least 50% in said transmission or infection of said virus relative to an untreated cell.
- Claim 2. The method of claim 1, wherein said immunodeficiency virus is human immunodeficiency virus (HIV), and said cell is a human cell.
- Claim 3. The method of claim 1, wherein said inhibitor of p21 is a polynucleotide.
- Claim 4. The method of claim 2, wherein said polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.
- Claim 5. The method of claim 3, wherein said p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule.
- Claim 6. The method of claim 5, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:4**.
- Claim 7. The method of claim 6, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:8** or **SEQ ID NO.:10**.
- Claim 8. The method of claim 3, wherein said p21 gene or p21 cDNA is of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.

- Claim 9. The method of claim 8, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:6**.
- Claim 10. The method of claim 9, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:7** or **SEQ ID NO.:9**.
- 5
- Claim 11. The method of claim 1, wherein said inhibitor of p21 is a protein or organic molecule other than a polynucleotide.
- Claim 12. The method of claim 11, wherein said inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.
- 10
- Claim 13. A method of treating AIDS in an individual, comprising providing to HIV-1 infected cells of said individual an amount of a p21 inhibitor sufficient to attenuate the propagation of HIV, wherein said inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least 50% in said propagation of HIV relative to untreated cells.
- 15
- Claim 14. The method of claim 10, wherein said inhibitor of p21 is a polynucleotide.
- Claim 15. The method of claim 11, wherein said polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.
- 20
- Claim 16. The method of claim 11, wherein said p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule.
- Claim 17. The method of claim 16, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:4**.

- Claim 18. The method of claim 17, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:8** or **SEQ ID NO.:10**.
- 5 Claim 19. The method of claim 11, wherein said p21 gene or p21 cDNA is of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.
- Claim 20. The method of claim 19, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:6**.
- 10 Claim 21. The method of claim 20, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:7** or **SEQ ID NO.:9**.
- Claim 22. The method of claim 13, wherein said inhibitor of p21 is a protein or organic molecule other than a polynucleotide.
- 15 Claim 23. The method of claim 22, wherein said inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.
- 20 Claim 24. A pharmaceutical composition comprising an inhibitor of p21 and an excipient or carrier, wherein said inhibitor is present in an amount sufficient to attenuate the propagation of HIV, wherein said inhibitor is present in said composition in an amount sufficient to cause an attenuation of at least 50% in said propagation of HIV relative to untreated cells.
- Claim 25. The composition of claim 24, wherein said inhibitor of p21 is a polynucleotide.
- 25 Claim 26. The composition of claim 25, wherein said polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.

- Claim 27. The composition of claim 25, wherein said p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule.
- Claim 28. The composition of claim 27, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:4**.
- 5 Claim 29. The composition of claim 28, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:8** or **SEQ ID NO.:10**.
- Claim 30. The composition of claim 25, wherein said p21 gene or p21 cDNA is of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.
- 10 Claim 31. The composition of claim 30, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:6**.
- Claim 32. The composition of claim 31, wherein said polynucleotide comprises at least 10 contiguous nucleotides of **SEQ ID NO.:7** or **SEQ ID NO.:9**.
- 15 Claim 33. The composition of claim 24, wherein said inhibitor of p21 is a protein or organic molecule other than a polynucleotide.
- Claim 34. The composition of claim 33, wherein said inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.
- 20

### **Abstract of the Invention**

This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKN1A) expression  
5 to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides and/or 2-cyano-3,12-dioxooleana-1,9-dien-28-oic (CDDO) to attenuate such replication.

1/11




Figure 1A




Figure 1B



2/11




Figure 1C




Figure 1D

3/11




Figure 2A




Figure 2B







Figure 2C



7/11




Figure 4A




Figure 4B

8/11




Figure 4C




Figure 4D

9/11




Figure 5A




Figure 5B



10/11

Figure 5C






Figure 5D

11/11




Figure 6